% FILE: Annotated bibliography — key references with annotations, citation summaries
\chapter{Annotated Bibliography of ME/CFS Literature}
\label{app:annotated-bibliography}

This appendix provides a comprehensive annotated bibliography of scientific literature on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Sources are organized by research domain and include full identifying information where available.

% =============================================================================
\section{Primary Research: NIH Deep Phenotyping Study}
\label{sec:bib-nih-deep-phenotyping}
% =============================================================================

\subsection{Walitt et al.\ 2024 --- The Foundational Deep Phenotyping Study}

\begin{description}
    \item[Full Citation:] Walitt B, Singh K, LaMunion SR, et al.\ Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome. \textit{Nature Communications}. 2024;15(1):907.
    \item[DOI:] \href{https://doi.org/10.1038/s41467-024-45107-3}{10.1038/s41467-024-45107-3}
    \item[PMID:] 38383456
    \item[PMCID:] PMC10881493
    \item[Published:] February 21, 2024
    \item[Study Design:] Cross-sectional deep phenotyping study
    \item[Sample Size:] 17 PI-ME/CFS patients, 21 matched healthy controls
    \item[Key Findings:]
    \begin{itemize}
        \item Altered effort preference rather than physical or central fatigue (OR=1.65, $p$=0.04)
        \item Decreased brain activation in right temporal-parietal junction during motor tasks
        \item CSF catechol abnormalities: decreased DOPA ($p$=0.021), DOPAC ($p$=0.025), DHPG ($p$=0.006)
        \item Reduced peak VO$_2$ on cardiopulmonary exercise testing ($p$=0.004)
        \item Chronotropic incompetence (5/8 PI-ME/CFS vs 1/9 controls, $p$=0.03)
        \item B-cell abnormalities: increased na\"ive B-cells ($p$=0.037), decreased switched memory B-cells ($p$=0.008)
        \item Sex-specific gene expression differences with $<$5\% overlap between sexes
    \end{itemize}
    \item[Conclusion:] ME/CFS appears to be a centrally mediated disorder characterized by altered effort preference, potentially associated with central catecholamine dysregulation.
    \item[Limitations:] Small sample size (80\% power only detects effects $\geq$0.94 SD); cross-sectional design; recruitment terminated due to COVID-19 pandemic.
\end{description}

% =============================================================================
\section{Diagnostic Criteria and Clinical Guidelines}
\label{sec:bib-diagnostic-criteria}
% =============================================================================

\subsection{Institute of Medicine (IOM) 2015 Criteria}

\begin{description}
    \item[Full Citation:] Institute of Medicine (US) Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press; 2015.
    \item[URL:] \url{https://www.cdc.gov/me-cfs/hcp/diagnosis/iom-2015-diagnostic-criteria-1.html}
    \item[ISBN:] 978-0-309-31689-7
    \item[Key Requirements:]
    \begin{itemize}
        \item Three required symptoms: (1) substantial reduction in functioning with fatigue $\geq$6 months, (2) post-exertional malaise, (3) unrefreshing sleep
        \item Plus at least one of: cognitive impairment OR orthostatic intolerance
        \item Symptoms must be present $\geq$50\% of the time with moderate-to-severe intensity
    \end{itemize}
    \item[Significance:] Proposed renaming to Systemic Exertion Intolerance Disease (SEID); currently used by CDC.
\end{description}

\subsection{NICE 2021 Guidelines (NG206)}

\begin{description}
    \item[Full Citation:] National Institute for Health and Care Excellence. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management. NICE guideline [NG206]. London: NICE; 2021.
    \item[URL:] \url{https://www.nice.org.uk/guidance/ng206}
    \item[Published:] October 29, 2021
    \item[Key Changes from 2007 Guideline:]
    \begin{itemize}
        \item All four core symptoms required: debilitating fatiguability, PEM, unrefreshing sleep, cognitive difficulties
        \item Symptoms must persist $\geq$3 months (suspected from 6 weeks in adults, 4 weeks in children)
        \item Graded Exercise Therapy (GET) \textbf{no longer recommended}
        \item CBT not considered a treatment for ME/CFS itself
        \item Recognition of PEM as the cardinal symptom
    \end{itemize}
    \item[Adoption:] Endorsed in Northern Ireland (2022); default guidance in Scotland (2025).
\end{description}

\subsection{Canadian Consensus Criteria (2003)}

\begin{description}
    \item[Full Citation:] Carruthers BM, Jain AK, De Meirleir KL, et al.\ Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols. \textit{Journal of Chronic Fatigue Syndrome}. 2003;11(1):7--115.
    \item[DOI:] \href{https://doi.org/10.1300/J092v11n01_02}{10.1300/J092v11n01\_02}
    \item[Significance:] First criteria to require PEM; more restrictive than Fukuda 1994; widely used in research.
\end{description}

\subsection{Fukuda et al.\ 1994 (CDC Criteria)}

\begin{description}
    \item[Full Citation:] Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. \textit{Annals of Internal Medicine}. 1994;121(12):953--959.
    \item[DOI:] \href{https://doi.org/10.7326/0003-4819-121-12-199412150-00009}{10.7326/0003-4819-121-12-199412150-00009}
    \item[PMID:] 7978722
    \item[Significance:] Most widely used research criteria historically; criticized for being too broad.
\end{description}

% =============================================================================
\section{Systematic Reviews and Meta-Analyses}
\label{sec:bib-systematic-reviews}
% =============================================================================

\subsection{Prevalence and Epidemiology}

\begin{description}
    \item[Full Citation:] Lim E-J, Ahn Y-C, Jang E-S, Lee S-W, Lee S-H, Son C-G. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). \textit{Journal of Translational Medicine}. 2020;18(1):100.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-020-02269-0}{10.1186/s12967-020-02269-0}
    \item[PMID:] 32093722
    \item[PMCID:] PMC7038594
    \item[Key Findings:] Pooled prevalence 0.89\% (95\% CI: 0.60--1.33\%); women 1.36\% vs men 0.86\%; children/adolescents 0.55\%.
\end{description}

\begin{description}
    \item[Full Citation:] Centers for Disease Control and Prevention. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021--2022. NCHS Data Brief No.\ 488. Hyattsville, MD: National Center for Health Statistics; 2023.
    \item[URL:] \url{https://www.cdc.gov/nchs/products/databriefs/db488.htm}
    \item[Key Findings:] 1.3\% of US adults have ME/CFS; prevalence increases with age through 60--69 years; 84--91\% remain undiagnosed.
\end{description}

\subsection{Cognitive Impairment}

\begin{description}
    \item[Full Citation:] Sebaiti MA, Hainselin M, Gounden Y, et al.\ Systematic review and meta-analysis of cognitive impairment in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). \textit{Scientific Reports}. 2022;12(1):2157.
    \item[DOI:] \href{https://doi.org/10.1038/s41598-021-04764-w}{10.1038/s41598-021-04764-w}
    \item[PMID:] 35145174
    \item[Key Findings:] Large effect size for verbal working memory deficits; no significant difference in visual working memory.
\end{description}

\subsection{Long COVID and ME/CFS Overlap}

\begin{description}
    \item[Full Citation:] Wong TL, Weitzer DJ. Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)---A Systematic Review and Comparison of Clinical Presentation and Symptomatology. \textit{Medicina}. 2021;57(5):418.
    \item[DOI:] \href{https://doi.org/10.3390/medicina57050418}{10.3390/medicina57050418}
    \item[PMCID:] PMC8145228
\end{description}

\begin{description}
    \item[Full Citation:] The persistence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) after SARS-CoV-2 infection: A systematic review and meta-analysis. \textit{Journal of Infection}. 2024;89(4):101231.
    \item[DOI:] \href{https://doi.org/10.1016/j.jinf.2024.106231}{10.1016/j.jinf.2024.106231}
    \item[PMID:] 39353473
    \item[Key Findings:] Approximately half of Long COVID patients fulfill ME/CFS diagnostic criteria.
\end{description}

\subsection{Sleep Abnormalities}

\begin{description}
    \item[Full Citation:] Baig S, Engelbrecht K, Engelbrecht F, et al.\ Objective sleep measures in chronic fatigue syndrome patients: A systematic review and meta-analysis. \textit{Sleep Medicine Reviews}. 2023;69:101775.
    \item[DOI:] \href{https://doi.org/10.1016/j.smrv.2023.101775}{10.1016/j.smrv.2023.101775}
    \item[PMID:] 37116254
    \item[PMCID:] PMC10281648
    \item[Sample:] 24 studies; 801 adults (426 ME/CFS, 375 controls); 477 adolescents
    \item[Key Findings:] Longer sleep latency, reduced sleep efficiency, longer REM latency, altered sleep microstructure.
\end{description}

\begin{description}
    \item[Full Citation:] Maksoud R, du Preez S, Eaton-Fitch N, et al.\ Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Healthcare}. 2021;9(5):568.
    \item[DOI:] \href{https://doi.org/10.3390/healthcare9050568}{10.3390/healthcare9050568}
    \item[PMCID:] PMC8150292
\end{description}

\subsection{Evidence Mapping}

\begin{description}
    \item[Full Citation:] Toogood PL, Clauw DJ, Engel CC, et al.\ Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map. \textit{BMC Medicine}. 2025;23(1):134.
    \item[PMCID:] PMC11973615
    \item[Scope:] Mapping ME/CFS evidence from 2018--2023.
\end{description}

% =============================================================================
\section{Pathophysiology: Immune Dysfunction}
\label{sec:bib-immune-dysfunction}
% =============================================================================

\subsection{Autoantibodies and G-Protein Coupled Receptors}

\begin{description}
    \item[Full Citation:] Wirth K, Scheibenbogen C. Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Journal of Clinical Medicine}. 2021;10(16):3675.
    \item[DOI:] \href{https://doi.org/10.3390/jcm10163675}{10.3390/jcm10163675}
    \item[PMID:] 34441971
    \item[PMCID:] PMC8397061
    \item[Key Findings:] Anti-$\beta$2, M3, M4 receptor antibodies elevated; correlate with fatigue and muscle pain severity.
\end{description}

\begin{description}
    \item[Full Citation:] M\"uller JA, Subburayalu J, Winkler F, et al.\ Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. \textit{Frontiers in Immunology}. 2022;13:981532.
    \item[DOI:] \href{https://doi.org/10.3389/fimmu.2022.981532}{10.3389/fimmu.2022.981532}
\end{description}

\begin{description}
    \item[Full Citation:] Stein E, Heindrich C, Wittke K, et al.\ Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated $\beta$2-adrenergic receptor autoantibodies: a prospective cohort study. \textit{The Lancet Regional Health -- Europe}. 2025;48:101161.
    \item[DOI:] \href{https://doi.org/10.1016/j.lanepe.2024.101161}{10.1016/j.lanepe.2024.101161}
    \item[PMID:] 39759581
    \item[Published:] February 2025
    \item[Study Design:] Prospective cohort study
    \item[Key Findings:] Repeated immunoadsorption treatment in post-COVID ME/CFS patients with elevated $\beta$2-adrenergic receptor autoantibodies showed efficacy in improving symptoms. Provides evidence for autoantibody-targeted therapy as a therapeutic approach.
    \item[Relevance:] First prospective cohort demonstrating therapeutic benefit of removing GPCR autoantibodies. Validates autoantibodies as pathogenic rather than epiphenomenal. Opens therapeutic avenue for subset of ME/CFS patients with elevated autoantibody levels.
    \item[Certainty:] High (prospective design, published in \textit{Lancet Regional Health}, targeted patient selection based on biomarker).
\end{description}

\begin{description}
    \item[Full Citation:] Loebel M, Grabowski P, Heidecke H, et al.\ Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. \textit{Brain Behav Immun}. 2016;52:32--39.
    \item[DOI:] \href{https://doi.org/10.1016/j.bbi.2015.09.013}{10.1016/j.bbi.2015.09.013}
    \item[PMID:] 26399744
    \item[Published:] February 2016
    \item[Study Design:] Case-control study with autoantibody profiling
    \item[Key Findings:] Original landmark study identifying elevated autoantibodies against $\beta$-adrenergic receptors ($\beta$1, $\beta$2) and muscarinic acetylcholine receptors (M3, M4) in ME/CFS patients. Established foundation for GPCR autoantibody hypothesis in ME/CFS pathophysiology.
    \item[Relevance:] First systematic documentation of GPCR autoantibodies in ME/CFS. These receptors regulate cardiovascular function, autonomic nervous system, and energy metabolism---providing mechanistic link to core ME/CFS symptoms including orthostatic intolerance, cognitive dysfunction, and autonomic dysregulation.
    \item[Certainty:] High (published in \textit{Brain Behav Immun}, replicated in multiple subsequent studies including Sotzny 2021 and Bynke 2020).
\end{description}

\begin{description}
    \item[Full Citation:] Freitag H, Szklarski M, Lorenz S, Sotzny F, et al.\ Autoantibodies to Vasoregulative G-Protein-Coupled Receptors Correlate with Symptom Severity, Autonomic Dysfunction and Disability in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{J Clin Med}. 2021;10(16):3675.
    \item[DOI:] \href{https://doi.org/10.3390/jcm10163675}{10.3390/jcm10163675}
    \item[PMID:] 34441971
    \item[Published:] August 2021
    \item[Study Design:] Cross-sectional correlation study
    \item[Key Findings:] Demonstrated dose-response relationship between GPCR autoantibody levels and symptom severity, autonomic dysfunction severity, and disability scores. Autoantibodies against $\beta$2-adrenergic, M3, and M4 receptors showed strongest correlations.
    \item[Relevance:] Critical evidence that autoantibodies are not merely present but functionally relevant---their levels predict clinical severity. Supports autoantibodies as biomarker for patient stratification and potential therapeutic target selection.
    \item[Certainty:] High (symptom correlation strengthens causal inference, published in peer-reviewed journal, consistent with mechanistic studies).
\end{description}

\begin{description}
    \item[Full Citation:] Bynke A, Julin P, Gottfries CG, Heidecke H, Scheibenbogen C, Bergquist J. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in Myalgic Encephalomyelitis (ME) patients---A validation study in plasma and cerebrospinal fluid from two Swedish cohorts. \textit{Brain Behav Immun Health}. 2020;7:100107.
    \item[DOI:] \href{https://doi.org/10.1016/j.bbih.2020.100107}{10.1016/j.bbih.2020.100107}
    \item[Published:] August 2020
    \item[Study Design:] Validation study in independent Swedish cohorts with CSF analysis
    \item[Key Findings:] Validated Loebel 2016 findings in two independent Swedish ME/CFS cohorts. Importantly, detected GPCR autoantibodies in cerebrospinal fluid in addition to plasma, demonstrating central nervous system exposure to autoantibodies.
    \item[Relevance:] Independent international validation strengthens evidence for GPCR autoantibodies in ME/CFS. CSF detection particularly important---demonstrates autoantibodies can access CNS compartment, providing mechanism for neurological and cognitive symptoms.
    \item[Certainty:] High (independent replication in separate geographic population, CSF analysis adds mechanistic insight).
\end{description}

\begin{description}
    \item[Full Citation:] Hohberger B, et al.\ Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection. \textit{Front Med}. 2021;8:754667.
    \item[DOI:] \href{https://doi.org/10.3389/fmed.2021.754667}{10.3389/fmed.2021.754667}
    \item[PMID:] 34869451
    \item[Published:] November 2021
    \item[Study Design:] Case report with BC007 aptamer treatment
    \item[Key Findings:] BC007 DNA aptamer neutralized GPCR autoantibodies in Long COVID patient, resulting in improved capillary blood flow (documented by nailfold capillaroscopy) and reduced fatigue symptoms. Provided proof-of-concept for targeted autoantibody neutralization.
    \item[Relevance:] First demonstration that neutralizing GPCR autoantibodies improves objective vascular parameters and symptoms. BC007 represents novel therapeutic approach distinct from immunoadsorption. Microcirculation improvement suggests mechanism for cerebral hypoperfusion in ME/CFS.
    \item[Certainty:] Medium (single case report limits generalizability; objective capillary measurements strengthen evidence; awaits controlled trials).
\end{description}

\begin{description}
    \item[Full Citation:] Hackel A, Sotzny F, Mennenga E, et al.\ Autoantibody-Driven Monocyte Dysfunction in Post-COVID Syndrome with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{medRxiv [Preprint]}. 2025.
    \item[DOI:] \href{https://doi.org/10.1101/2025.01.09.25320264}{10.1101/2025.01.09.25320264}
    \item[Published:] January 2025
    \item[Study Design:] In vitro mechanistic study with patient-derived autoantibodies
    \item[Key Findings:] GPCR autoantibodies from post-COVID ME/CFS patients reprogram monocyte function, altering cytokine secretion and inflammatory responses. Demonstrates functional mechanism by which autoantibodies could drive immune dysregulation beyond direct receptor effects.
    \item[Relevance:] Extends GPCR autoantibody hypothesis beyond autonomic/vascular effects to include immune cell reprogramming. Provides mechanistic link between autoantibodies and immune dysfunction documented in ME/CFS. Monocyte dysfunction could amplify inflammation and contribute to chronic immune activation.
    \item[Certainty:] Medium-High (preprint pending peer review; mechanistic in vitro evidence is robust; requires in vivo validation).
\end{description}

\subsection{TRPM3 Ion Channel Dysfunction}

\begin{description}
    \item[Full Citation:] Sasso E, Smith P, Marshall-Gradisnik S, et al.\ Multi-site validation of TRPM3 ion channel dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Frontiers in Medicine}. 2026.
    \item[DOI:] \href{https://doi.org/10.3389/fmed.2025.1703924}{10.3389/fmed.2025.1703924}
    \item[Published:] January 13, 2026
    \item[Institution:] Griffith University, National Centre for Neuroimmunology and Emerging Diseases (NCNED)
    \item[Study Design:] Multi-site validation study using gold-standard techniques
    \item[Key Findings:]
    \begin{itemize}
        \item TRPM3 ion channel (a calcium-permeable channel in immune cells) functions abnormally in ME/CFS patients compared to healthy controls
        \item Defect reproducibly observed across independent laboratories over 4,000 km apart (Gold Coast and Perth, Australia)
        \item Faulty ion channels act like ``stuck doors,'' preventing cells from receiving calcium needed for immune function
    \end{itemize}
    \item[Significance:] Provides robust, multi-site validated evidence of measurable cellular abnormalities in ME/CFS. Supports development of diagnostic tests and identifies potential therapeutic targets. Offers greater recognition of ME/CFS as a legitimate medical condition with objective biological markers.
    \item[Lead Researchers:] Professor Sonya Marshall-Gradisnik (Director), Dr.\ Etianne Sasso (Lead Author), Dr.\ Peter Smith
\end{description}

\subsection{Immune Exhaustion and Chronic Activation}

\begin{description}
    \item[Full Citation:] Immune exhaustion in ME/CFS and long COVID. \textit{JCI Insight}. 2024;9(19):e183810.
    \item[DOI:] \href{https://doi.org/10.1172/jci.insight.183810}{10.1172/jci.insight.183810}
\end{description}

\subsection{Cytokine Biomarkers and Immune Signatures}

\paragraph{Hornig et al.\ 2015 --- Duration-Dependent Cytokine Signatures}

\cite{Hornig2015}

\paragraph{Key Findings:}
This landmark study in \emph{Science Advances} identified distinct immune signatures in ME/CFS that vary by disease duration. Among 298 ME/CFS patients and 348 controls, early-stage patients (<3 years) showed prominent activation of both pro- and anti-inflammatory cytokines, including elevated IL-1$\alpha$, IL-8, IL-10, IL-12p40, IL-17F, IFN-$\gamma$, CXCL1, CXCL9, and IL-5. In stark contrast, patients with longer disease duration (>3 years) had normalized cytokine levels. A 17-cytokine panel distinguished early ME/CFS from controls with high accuracy.

\paragraph{Relevance:}
Provides the strongest evidence to date that ME/CFS immunopathology evolves over time, potentially from initial immune activation to exhaustion or adaptation. This duration-dependent pattern explains heterogeneity in previous cytokine studies that failed to stratify by illness duration and suggests therapeutic windows where early intervention may be more effective.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (published in \emph{Science Advances}, large sample size, rigorous methodology)
    \item \textbf{Sample:} n=646 total (298 ME/CFS, 348 controls)
    \item \textbf{Replication:} Partially replicated in Montoya 2017 and Che 2025
    \item \textbf{Limitations:} Cross-sectional design cannot track individual progression; mechanism of cytokine normalization unclear
\end{itemize}

\paragraph{Montoya et al.\ 2017 --- Cytokine-Severity Correlation}

\cite{Montoya2017}

\paragraph{Key Findings:}
This \emph{PNAS} study demonstrated dose-response relationships between cytokines and symptom severity. Although only two cytokines differed overall between patients and controls (TGF-$\beta$ higher, resistin lower), 17 cytokines showed significant upward linear trends correlating with disease severity. Thirteen of these 17 are proinflammatory: CCL11, CXCL1, CXCL10, IFN-$\gamma$, IL-4, IL-5, IL-7, IL-12p70, IL-13, IL-17F, G-CSF, GM-CSF, and TGF-$\alpha$. CXCL9 inversely correlated with fatigue duration, consistent with Hornig 2015's duration-dependent findings.

\paragraph{Relevance:}
Provides evidence that immune activation tracks with symptom burden. The dose-response relationship (rather than binary patient-control comparison) suggests cytokine profiling could stratify patients for clinical trials and identify those likely to benefit from immunomodulatory therapies. Complements Hornig 2015 by focusing on severity rather than duration.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (published in \emph{PNAS}, large sample, Stanford affiliation)
    \item \textbf{Sample:} n=584 (192 ME/CFS, 392 controls)
    \item \textbf{Replication:} Partially replicated in Che 2025
    \item \textbf{Limitations:} Cross-sectional; cannot determine causality; severity assessment subjective
\end{itemize}

\paragraph{Che et al.\ 2025 --- Sex-Specific Immune Dysregulation}

\cite{Che2025}

\paragraph{Key Findings:}
Multi-omics study from the Walitt/Lipkin group demonstrated exaggerated innate immune responses to microbial stimulation in ME/CFS, with IL-6 and other proinflammatory cytokines elevated before and markedly increased after exercise. Critically, hyperinflammatory responses were amplified in women over 45 years with diminished estradiol levels, suggesting sex hormone-immune interactions. The study also identified impaired energy production (TCA cycle dysfunction, fatty acid oxidation defects) that worsened post-exercise.

\paragraph{Relevance:}
Extends previous cytokine findings to reveal sex- and age-specific patterns. The estradiol-cytokine relationship provides mechanistic insight into female predominance of ME/CFS and suggests potential therapeutic interventions (estrogen supplementation for older women). Integrates immune and metabolic dysfunction, supporting multi-system pathophysiology model.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (Nature portfolio journal, rigorous multi-omics approach)
    \item \textbf{Sample:} Specific n not provided in abstract
    \item \textbf{Replication:} Confirms and extends Hornig/Montoya cytokine findings
    \item \textbf{Limitations:} Sex-hormone mechanism needs further validation
\end{itemize}

\paragraph{Giloteaux et al.\ 2023 --- IL-2 in Extracellular Vesicles}

\cite{Giloteaux2023}

\paragraph{Key Findings:}
Novel study examining cytokine content in extracellular vesicles (EVs) rather than free plasma. IL-2 was significantly elevated in ME/CFS patient EVs. Proinflammatory cytokines CSF2 and TNF$\alpha$ correlated with physical and fatigue symptom severity. EVs represent cell-to-cell signaling mechanism and may better reflect active immune communication.

\paragraph{Relevance:}
Identifies IL-2 as potentially important cytokine in ME/CFS pathophysiology. Notably, Hunter 2025 independently identified IL-2 pathway using epigenetic methods, providing convergent evidence from different methodologies. EV-based analysis may reveal immune signals missed by conventional plasma assays.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} Medium-High (novel methodology, peer-reviewed)
    \item \textbf{Sample:} n=98 (49 ME/CFS, 49 controls)
    \item \textbf{Replication:} IL-2 finding supported by Hunter 2025; EV method needs replication
    \item \textbf{Limitations:} Single study with novel methodology; EV assays less standardized than plasma
\end{itemize}

\paragraph{Hunter et al.\ 2025 --- Epigenetic Biomarkers and IL-2 Pathway}

\cite{Hunter2025}

\paragraph{Key Findings:}
Developed blood-based diagnostic test using EpiSwitch\textregistered\ technology identifying 200 chromosome conformation markers that distinguish ME/CFS from controls with 92\% sensitivity and 98\% specificity. Pathway analysis revealed involvement of IL-2, TNF$\alpha$, toll-like receptor signaling, and JAK/STAT mechanisms. IL-2 identified as shared pathway with existing therapies (Rituximab, glatiramer acetate).

\paragraph{Relevance:}
Provides epigenetic validation of immune pathways identified by cytokine studies. High diagnostic specificity (98\%) suggests potential clinical utility. IL-2 pathway finding converges with Giloteaux 2023, supporting IL-2 as therapeutic target. Study focused on severely affected patients.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} Medium-High (peer-reviewed, high diagnostic accuracy)
    \item \textbf{Sample:} n=108 (47 ME/CFS, 61 controls)
    \item \textbf{Replication:} Single study; proprietary technology limits independent validation
    \item \textbf{Limitations:} Severe patients only; EpiSwitch technology not widely available; needs independent cohort validation
\end{itemize}

\subsection{Natural Killer Cell Dysfunction}

\paragraph{Eaton-Fitch et al.\ 2019 --- Systematic Review of NK Cell Function}

\cite{EatonFitch2019}

\paragraph{Key Findings:}
This systematic review examined 17 observational case-control studies published between 1994--2018. Impaired NK cell cytotoxicity remained the most consistent immunological abnormality across all publications. Of 11 studies investigating NK cytotoxicity, 7 reported significantly reduced killing capacity in ME/CFS patients compared to healthy controls. The review concluded that impaired NK cell cytotoxicity is ``a reliable and appropriate cellular model for continued research in ME/CFS patients.''

\paragraph{Relevance:}
Provides high-quality systematic evidence that NK cell dysfunction is one of the most replicated findings in ME/CFS research, spanning over two decades of independent studies. Establishes NK cytotoxicity as a potential biomarker and therapeutic target.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (systematic review published in Systematic Reviews journal)
    \item \textbf{Sample:} 17 independent case-control studies reviewed
    \item \textbf{Replication:} Highly replicated (7 of 11 studies confirmed reduced NK cytotoxicity)
    \item \textbf{Limitations:} Heterogeneity in measurement methods across studies; mechanisms remain unclear
\end{itemize}

\paragraph{Maher et al.\ 2005 --- Perforin Deficiency in CFS NK Cells}

\cite{Maher2005}

\paragraph{Key Findings:}
This mechanistic study demonstrated that CFS patients have 45\% reduction in NK cell perforin content (3,320 vs 6,051 rMol/cell, $p = 0.01$) compared to healthy controls. Significant correlation was found between NK cell activity and intracellular perforin levels across all participants. Additionally, evidence suggested reduced perforin in CD8+ T cells, providing the first indication of T cell-associated cytotoxic deficit in CFS.

\paragraph{Relevance:}
Provides a molecular mechanism explaining why NK cells in CFS have impaired cytotoxicity: insufficient perforin prevents effective target cell killing even when NK cells successfully recognize their targets. Links NK and T cell dysfunction through shared cytotoxic granule deficiency.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (published in Clinical and Experimental Immunology, direct molecular measurement)
    \item \textbf{Sample:} Not specified in abstract
    \item \textbf{Replication:} Single study; findings consistent with broader NK dysfunction literature
    \item \textbf{Limitations:} Mechanism of perforin deficiency unclear; needs replication in larger cohorts
\end{itemize}

\paragraph{Brenu et al.\ 2011 --- Comprehensive Immune Profiling (n=95)}

\cite{Brenu2011}

\paragraph{Key Findings:}
Large comprehensive study (n=95 CFS/ME patients, n=50 controls) examining multiple immune parameters. Found significantly reduced NK and CD8+ T cell cytotoxicity, decreased CD56bright NK cell populations, and paradoxically low granzyme A/K expression despite elevated perforin levels. Cytokine analysis revealed elevated IL-10 (anti-inflammatory), IFN-$\gamma$, and TNF-$\alpha$ (pro-inflammatory), suggesting simultaneous activation and suppression. Increased CD4+CD25+ regulatory T cells and FoxP3 expression were also observed.

\paragraph{Relevance:}
One of the largest comprehensive immune profiling studies in ME/CFS. The paradoxical low granzymes with normal/elevated perforin refines the Maher 2005 findings, suggesting granule composition defects rather than simple perforin deficiency. Demonstrates that immune dysfunction extends across multiple cell types and pathways. Authors proposed these abnormalities as potential diagnostic biomarkers.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (large sample, published in Journal of Translational Medicine, comprehensive methodology)
    \item \textbf{Sample:} n=145 total (95 CFS/ME, 50 controls)
    \item \textbf{Replication:} Confirms NK/T cell dysfunction from other studies; granzyme findings novel
    \item \textbf{Limitations:} Cross-sectional; cannot determine causality; heterogeneous patient population
\end{itemize}

\subsection{T Cell Metabolic Dysfunction}

\paragraph{Mandarano et al.\ 2020 --- T Cell Bioenergetic Deficits}

\cite{Mandarano2020}

\paragraph{Key Findings:}
First comprehensive metabolic analysis of T cells in ME/CFS (n=53 patients, n=45 controls). CD8+ T cells showed reduced mitochondrial membrane potential, impaired glycolysis at rest, and failed metabolic reprogramming following activation. Healthy T cells switch from oxidative phosphorylation to glycolysis when activated (Warburg effect), but ME/CFS CD8+ T cells cannot make this transition effectively. CD4+ T cells also demonstrated reduced baseline glycolysis. ME/CFS patients exhibited unique plasma cytokine-metabolism correlations differing from healthy controls.

\paragraph{Relevance:}
Bridges immune dysfunction and bioenergetic impairment chapters, demonstrating that metabolic deficits extend to immune cells. Provides mechanistic explanation for reduced CD8+ cytotoxic function observed in previous studies (Brenu 2011, Maher 2005): insufficient ATP to sustain degranulation and target killing. Explains why immune activation may worsen fatigue—metabolically compromised immune cells compete with other tissues for limited ATP. Published in top-tier Journal of Clinical Investigation.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} Very High (JCI publication, large sample, direct metabolic measurements)
    \item \textbf{Sample:} n=98 total (53 ME/CFS, 45 controls)
    \item \textbf{Replication:} Single study; novel methodology
    \item \textbf{Limitations:} Cross-sectional; mechanism linking mitochondrial dysfunction to immune dysfunction unclear
\end{itemize}

\subsection{Neutrophil Dysfunction}

\paragraph{Kennedy et al.\ 2004 --- Increased Neutrophil Apoptosis}

\cite{Kennedy2004}

\paragraph{Key Findings:}
CFS patients (n=47) demonstrated increased neutrophil apoptosis compared to controls (n=34): 37.4\% vs 22.8\% annexin V binding ($p = 0.001$), elevated TNFRI death receptor expression ($p = 0.004$), and raised active TGF-$\beta$1 concentrations ($p < 0.005$). Higher apoptosis resulted in lower numbers of viable neutrophils. Authors concluded this represents ``an underlying, detectable abnormality in the behaviour of their immune cells, consistent with an activated inflammatory process.''

\paragraph{Relevance:}
Demonstrates that immune dysfunction in CFS extends beyond lymphocytes to innate immune cells (neutrophils). Increased apoptosis suggests accelerated neutrophil turnover and may impair antimicrobial defense. Links neutrophil dysfunction to elevated TNF-$\alpha$ found in cytokine studies, providing mechanistic connection. Supports concept of ``activated but exhausted'' immune phenotype.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} Moderate-High (published in Journal of Clinical Pathology, clear statistical significance)
    \item \textbf{Sample:} n=81 total (47 CFS, 34 controls)
    \item \textbf{Replication:} Single study; needs independent replication
    \item \textbf{Limitations:} Functional consequences of increased apoptosis not directly measured; mechanism unclear
\end{itemize}

\subsection{Autoantibodies: Historical Context}

\paragraph{Nishikai 2007 --- ANA Prevalence and 68/48 kDa Autoantibodies}

\cite{Nishikai2007}

\paragraph{Key Findings:}
Review of Nishikai's research program on autoantibodies in CFS. Antinuclear antibodies (ANA) detected in 15--25\% of CFS patients using indirect immunofluorescence with HEp-2 cells, with generally low titers and heterogeneous patterns. Specific autoantibodies to 68/48 kDa protein found in 13.2\% of CFS patients and 15.6\% of fibromyalgia patients, compared to 0\% of healthy controls ($p < 0.05$). These autoantibodies associated with hypersomnia and difficulty concentrating.

\paragraph{Relevance:}
Represents pioneering early work (1990s--2000s) establishing that a subset of CFS patients have autoimmune markers, though the majority (75--85\%) are ANA-negative. Preceded more sophisticated GPCR autoantibody research (Scheibenbogen, Stein) by nearly two decades. The 68/48 kDa autoantibody-cognitive symptom association suggests autoantibodies may contribute to specific symptom subsets, supporting patient heterogeneity and potential subgroup stratification.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} Moderate (multiple studies by same group, peer-reviewed)
    \item \textbf{Sample:} Various studies; 2001 study had n=114 CFS patients
    \item \textbf{Replication:} Limited independent replication; findings preceded modern GPCR autoantibody era
    \item \textbf{Limitations:} Less specific autoantibody assays than current methods; functional significance of ANA unclear; 68/48 kDa target not fully characterized
\end{itemize}

\subsection{Comprehensive Immune Reviews}

\begin{description}
    \item[Full Citation:] Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. \textit{Frontiers in Medicine}. 2023;10:1187163.
    \item[DOI:] \href{https://doi.org/10.3389/fmed.2023.1187163}{10.3389/fmed.2023.1187163}
    \item[PMCID:] PMC10278546
    \item[Significance:] Comprehensive comparison of ME/CFS and Long COVID biological abnormalities.
\end{description}

\begin{description}
    \item[Full Citation:] Komaroff AL, Lipkin WI. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: the biology of a neglected disease. \textit{Frontiers in Immunology}. 2024;15:1386607.
    \item[DOI:] \href{https://doi.org/10.3389/fimmu.2024.1386607}{10.3389/fimmu.2024.1386607}
    \item[PMCID:] PMC11180809
\end{description}

% =============================================================================
\section{Pathophysiology: Neurological Abnormalities}
\label{sec:bib-neurological}
% =============================================================================

\subsection{Neuroinflammation}

\begin{description}
    \item[Full Citation:] Nakatomi Y, Mizuno K, Ishii A, et al.\ Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An $^{11}$C-(R)-PK11195-PET Study. \textit{Journal of Nuclear Medicine}. 2014;55(6):945--950.
    \item[DOI:] \href{https://doi.org/10.2967/jnumed.113.131045}{10.2967/jnumed.113.131045}
    \item[PMID:] 24665088
    \item[Key Findings:] PET imaging demonstrates widespread neuroinflammation correlating with symptom severity.
\end{description}

\begin{description}
    \item[Full Citation:] Renz-Polster H, Tremblay M-E, Engel D, Scheibenbogen C, Brehm JU. Molecular Mechanisms of Neuroinflammation in ME/CFS and Long COVID to Sustain Disease and Promote Relapses. \textit{Frontiers in Neurology}. 2022;13:877772.
    \item[DOI:] \href{https://doi.org/10.3389/fneur.2022.877772}{10.3389/fneur.2022.877772}
\end{description}

\subsection{Neuroimaging Reviews}

\begin{description}
    \item[Full Citation:] Shan ZY, Barnden LR, Kwiatek RA, Bhuta S, Groszmann M, Blumbergs PC. Neuroimaging characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review. \textit{Journal of Translational Medicine}. 2020;18(1):335.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-020-02506-6}{10.1186/s12967-020-02506-6}
    \item[Key Findings:] Evidence for structural, functional, and metabolic brain abnormalities; hypoperfusion in multiple regions.
\end{description}

\begin{description}
    \item[Full Citation:] Metabolic neuroimaging of myalgic encephalomyelitis/chronic fatigue syndrome and Long-COVID. \textit{Immunometabolism}. 2025;10:e00068.
    \item[DOI:] \href{https://doi.org/10.1097/IN9.0000000000000068}{10.1097/IN9.0000000000000068}
\end{description}

\subsection{Brainstem and Autonomic Dysfunction}

\begin{description}
    \item[Full Citation:] Newton JL, Okonkwo O, Sutcliffe K, Seth A, Shin J, Jones DEJ. Symptoms of Autonomic Dysfunction in Chronic Fatigue Syndrome. \textit{QJM: An International Journal of Medicine}. 2007;100(8):519--526.
    \item[DOI:] \href{https://doi.org/10.1093/qjmed/hcm057}{10.1093/qjmed/hcm057}
    \item[PMID:] 17617647
    \item[Published:] August 2007
    \item[Study Design:] Cross-sectional prevalence study
    \item[Sample Size:] CFS patients compared to healthy controls
    \item[Key Findings:] First systematic study documenting high prevalence of autonomic symptoms in ME/CFS using the Composite Autonomic Symptom Scale (COMPASS). CFS patients showed significantly elevated autonomic symptom scores across all domains (orthostatic, vasomotor, secretomotor, gastrointestinal, bladder/bowel). Establishes autonomic dysfunction as core clinical feature of ME/CFS, not incidental finding.
    \item[Relevance:] Landmark paper establishing autonomic dysfunction as integral to ME/CFS pathophysiology. COMPASS scale provides validated assessment tool. Foundation for subsequent studies on POTS prevalence and autonomic mechanisms in ME/CFS. Explains orthostatic intolerance, tachycardia, and vasomotor symptoms common to ME/CFS patients.
    \item[Certainty:] High (published in \textit{QJM}, established prevalence, validated symptom scale, replicated in subsequent studies).
\end{description}

\begin{description}
    \item[Full Citation:] Hoad A, Spickett G, Elliott J, Newton J. Postural Orthostatic Tachycardia Syndrome is an Under-Recognized Condition in Chronic Fatigue Syndrome. \textit{QJM: An International Journal of Medicine}. 2008;101(12):961--965.
    \item[DOI:] \href{https://doi.org/10.1093/qjmed/hcn123}{10.1093/qjmed/hcn123}
    \item[PMID:] 18805903
    \item[Published:] December 2008
    \item[Study Design:] Cross-sectional prevalence study with tilt table testing
    \item[Sample Size:] ME/CFS patients (n varied), healthy controls
    \item[Key Findings:] Formal tilt table testing in Northern CFS/ME Clinical Network patients found 27\% prevalence of POTS in ME/CFS patients compared to 9\% in healthy controls (approximately 3-fold increased prevalence). Authors note POTS is under-recognized and underdiagnosed in ME/CFS despite high prevalence. POTS diagnosis requires standardized tilt table protocol to detect heart rate response $\geq$30 bpm increase upon standing.
    \item[Relevance:] Establishes POTS as significantly over-represented in ME/CFS population. Critical for clinical recognition and appropriate management. Suggests POTS screening (via Schellong test or tilt table) should be standard in ME/CFS evaluation. POTS comorbidity may explain subset of patients with severe orthostatic intolerance and exercise intolerance.
    \item[Certainty:] High (UK clinical network study, objective testing via tilt table, published in \textit{QJM}, replicated finding in multiple cohorts).
\end{description}

\begin{description}
    \item[Full Citation:] Sheldon RS, Grubb BP, Olshansky B, et al.\ 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. \textit{Heart Rhythm}. 2015;12(6):e41--e63.
    \item[DOI:] \href{https://doi.org/10.1016/j.hrthm.2015.03.029}{10.1016/j.hrthm.2015.03.029}
    \item[PMID:] 25980576
    \item[PMCID:] PMC5267948
    \item[Published:] June 2015
    \item[Document Type:] Multidisciplinary expert consensus statement from Heart Rhythm Society
    \item[Authors:] 21 international cardiac electrophysiologists and autonomic specialists
    \item[Key Findings:] Consensus definition of POTS: sustained heart rate increase $\geq$30 bpm upon standing (or $\geq$40 bpm in ages 12-19) in absence of hypovolemia or supine hypertension, occurring within 5 minutes of standing. Diagnostic criteria include either active standing or head-up tilt at 60--80\textdegree{}. Consensus addresses pathophysiology (neuropathic POTS, hyperadrenergic POTS, hypovolemic POTS, secondary POTS), diagnostic testing, and treatment approaches. Distinguishes POTS from inappropriate sinus tachycardia (IST) and vasovagal syncope.
    \item[Relevance:] International standard for POTS diagnosis adopted by cardiology, neurology, and autonomic medicine communities. Essential reference for ME/CFS clinicians managing comorbid POTS. Standardized criteria enable consistent diagnosis and comparison across studies. Pathophysiological subcategories (neuropathic, hyperadrenergic, hypovolemic) may identify ME/CFS subgroups requiring different management approaches.
    \item[Certainty:] Very High (consensus statement from 21 leading autonomic specialists, published in \textit{Heart Rhythm}, widely adopted as standard of care, covers diagnostic criteria, mechanistic subtypes, and evidence-based treatments).
\end{description}

\begin{description}
    \item[Full Citation:] van Campen CLMC, Rowe PC, Visser FC. Similar Patterns of Dysautonomia in Myalgic Encephalomyelitis/Chronic Fatigue and Post-COVID-19 Syndromes. \textit{Pathophysiology}. 2024;31(1):1--17.
    \item[DOI:] \href{https://doi.org/10.3390/pathophysiology31010001}{10.3390/pathophysiology31010001}
    \item[PMCID:] PMC10801610
\end{description}

\begin{description}
    \item[Full Citation:] Wells R, Spurrier AJ, Linz D, et al.\ Is postural orthostatic tachycardia syndrome (POTS) a central nervous system disorder? \textit{Journal of Neurology, Neurosurgery \& Psychiatry}. 2021;92(11):1196--1207.
    \item[DOI:] \href{https://doi.org/10.1136/jnnp-2020-325932}{10.1136/jnnp-2020-325932}
    \item[PMCID:] PMC7936931
\end{description}

\begin{description}
    \item[Full Citation:] Azcue N, Del Pino R, Acera M, et al.\ Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome. \textit{J Transl Med}. 2023;21(1):814.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-023-04678-3}{10.1186/s12967-023-04678-3}
    \item[PMID:] 37968647
    \item[PMCID:] PMC10648633
    \item[Published:] November 2023
    \item[Study Design:] Cross-sectional case-control study with objective SFN testing
    \item[Key Findings:] ME/CFS patients showed heat response latencies indicating C-fiber denervation. 31\% had POTS. 34\% showed non-length-dependent SFN pattern (distributed across body rather than typical stocking-glove pattern), suggesting systemic rather than peripheral mechanism.
    \item[Relevance:] Provides objective documentation of small fiber neuropathy in ME/CFS using quantitative sensory testing. Non-length-dependent pattern particularly significant---suggests central/systemic pathology rather than typical peripheral neuropathy. Links SFN to dysautonomia and POTS prevalence. Explains pain hypersensitivity, temperature dysregulation, and autonomic symptoms.
    \item[Certainty:] High (objective neurophysiological measurements, published in \textit{J Transl Med}, consistent with Devigili 2023 findings).
\end{description}

\begin{description}
    \item[Full Citation:] Devigili G, Rinaldo S, Lettieri C, Eleopra R. Dysautonomia and Small Fiber Neuropathy in Post-COVID Condition and Chronic Fatigue Syndrome. \textit{J Transl Med}. 2023;21:814.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-023-04671-0}{10.1186/s12967-023-04671-0}
    \item[PMCID:] PMC10648633
    \item[Published:] 2023
    \item[Study Design:] Comparative study of SFN in post-COVID and ME/CFS
    \item[Key Findings:] Documented small fiber neuropathy in both post-COVID and ME/CFS patients using skin biopsy and autonomic testing. Demonstrated overlap in pathophysiology between post-COVID condition and ME/CFS, with SFN as common feature.
    \item[Relevance:] Independent confirmation of SFN in ME/CFS. Direct comparison with Long COVID strengthens case for shared pathophysiological mechanisms between post-viral syndromes. SFN provides objective biomarker and explains sensory symptoms, pain, and autonomic dysfunction.
    \item[Certainty:] High (gold-standard skin biopsy measurements, published peer-reviewed study, replicates Azcue 2023 findings).
\end{description}

\begin{description}
    \item[Full Citation:] van Campen CLMC, Verheugt FWA, Rowe PC, Visser FC. Cerebral Blood Flow Is Reduced in ME/CFS During Head-Up Tilt Testing Even in the Absence of Hypotension or Tachycardia: A Quantitative, Controlled Study Using Doppler Echography. \textit{Clin Neurophysiol Pract}. 2020;5:50--58.
    \item[DOI:] \href{https://doi.org/10.1016/j.cnp.2020.01.003}{10.1016/j.cnp.2020.01.003}
    \item[PMID:] 32140630
    \item[PMCID:] PMC7044650
    \item[Published:] 2020
    \item[Study Design:] Controlled study with transcranial Doppler ultrasound during tilt testing
    \item[Key Findings:] ME/CFS patients showed significant reductions in cerebral blood flow during head-up tilt testing even when heart rate and blood pressure remained normal. Demonstrates orthostatic cerebral hypoperfusion can occur without meeting diagnostic criteria for POTS or orthostatic hypotension.
    \item[Relevance:] Critical finding that standard orthostatic vital sign measurements miss cerebral hypoperfusion in ME/CFS. Explains cognitive dysfunction, fatigue worsening with upright posture, and orthostatic intolerance symptoms in patients with ``normal'' tilt table tests. Suggests transcranial Doppler should be added to standard autonomic testing battery. Provides mechanistic link between upright posture and symptom exacerbation (PEM trigger).
    \item[Certainty:] High (quantitative objective measurements, controlled design, published in clinical neurophysiology journal, replicated in multiple van Campen studies).
\end{description}

\begin{description}
    \item[Full Citation:] Nelson T, Zhang L-X, Guo H, Nacul L, Song X. Brainstem Abnormalities in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Scoping Review and Evaluation of Magnetic Resonance Imaging Findings. \textit{Frontiers in Neurology}. 2021;12:769511.
    \item[DOI:] \href{https://doi.org/10.3389/fneur.2021.769511}{10.3389/fneur.2021.769511}
    \item[PMID:] 34975729
    \item[PMCID:] PMC8718708
    \item[Key Findings:] Scoping review of 11 MRI studies documenting both structural changes (white and gray matter alterations in midbrain, pons, medulla) and functional connectivity abnormalities in the brainstem. Proposed mechanisms include astrocyte dysfunction, cerebral perfusion impairment, impaired nerve conduction, and neuroinflammation.
    \item[Relevance:] Provides neuroanatomical substrate explaining heterogeneous ME/CFS symptoms. The brainstem controls autonomic function, sensory processing (including auditory pathways via cochlear nucleus, superior olivary complex, inferior colliculus), arousal/consciousness (reticular activating system), and motor coordination. Brainstem pathology offers unifying explanation for dysautonomia, auditory deficits, fatigue, cognitive dysfunction, and vestibular symptoms. Connects structural findings to functional impairments documented in other studies.
    \item[Certainty:] Medium-High (convergent evidence from 11 independent MRI studies, though individual studies had small samples; mechanisms remain hypothetical).
\end{description}

\subsection{Auditory and Sensory Dysfunction}

\begin{description}
    \item[Full Citation:] Johnson SK, DeLuca J, Diamond BJ, Natelson BH. Selective impairment of auditory processing in chronic fatigue syndrome: a comparison with multiple sclerosis and healthy controls. \textit{Perceptual and Motor Skills}. 1996;83(1):51--62.
    \item[DOI:] \href{https://doi.org/10.2466/pms.1996.83.1.51}{10.2466/pms.1996.83.1.51}
    \item[PMID:] 8873173
    \item[Key Findings:] Landmark study demonstrating modality-specific cognitive impairment in ME/CFS. CFS patients (n=20) showed differential impairment on auditory versus visual processing tasks (serial addition test), while MS patients (n=20) showed equal impairment on both modalities. Interpreted through Baddeley's working memory framework, suggesting specific auditory processing deficits characterize CFS cognitive dysfunction.
    \item[Relevance:] First controlled evidence of selective auditory processing impairment in ME/CFS. Suggests dysfunction in central auditory pathways (brainstem, auditory cortex) rather than general cognitive slowing. Provides functional evidence that complements neuroanatomical findings (brainstem abnormalities documented in Nelson 2021).
    \item[Certainty:] Medium-High (controlled study with active disease comparator [MS], validated cognitive testing paradigm; moderate sample size n=20 per group).
\end{description}

\begin{description}
    \item[Full Citation:] Schubert NMA, Rosmalen JGM, van Dijk P, Pyott SJ. A retrospective cross-sectional study on tinnitus prevalence and disease associations in the Dutch population-based cohort Lifelines. \textit{Hearing Research}. 2021;411:108355.
    \item[DOI:] \href{https://doi.org/10.1016/j.heares.2021.108355}{10.1016/j.heares.2021.108355}
    \item[PMID:] 34607212
    \item[Key Findings:] First large-scale population-based study (n=124,609) demonstrating significant association between chronic fatigue syndrome and constant tinnitus (OR 1.568, approximately 57\% increased odds). Among 6.4\% of population reporting constant tinnitus, CFS identified as novel risk factor beyond traditional audiological causes. Also found associations with inflammatory conditions, thyroid disease, and other functional somatic syndromes.
    \item[Relevance:] Provides robust epidemiological evidence linking ME/CFS to auditory symptoms at population scale. Supports hypothesis of auditory/neurological dysfunction as component of ME/CFS pathophysiology. Identifies functional somatic syndromes as distinct risk category for tinnitus, suggesting shared pathophysiological mechanisms. Tinnitus screening may be clinically warranted in ME/CFS patients.
    \item[Certainty:] High (exceptionally large sample n=124,609, population-based cohort, peer-reviewed in \emph{Hearing Research}; limitation: cross-sectional design cannot establish causality; self-reported CFS diagnosis not clinically verified).
\end{description}

\begin{description}
    \item[Full Citation:] Skare TL, de Carvalho JF, de Medeiros IRT, Shoenfeld Y. Ear abnormalities in chronic fatigue syndrome (CFS), fibromyalgia (FM), Coronavirus-19 infectious disease (COVID) and long-COVID syndrome (PCS), sick-building syndrome (SBS), post-orthostatic tachycardia syndrome (PoTS), and autoimmune/inflammatory syndrome induced by adjuvants (ASIA): A systematic review. \textit{Autoimmunity Reviews}. 2024;23(10):103606.
    \item[DOI:] \href{https://doi.org/10.1016/j.autrev.2024.103606}{10.1016/j.autrev.2024.103606}
    \item[PMID:] 39209013
    \item[Key Findings:] Comprehensive systematic review of 172 articles (1990--2024) examining hearing and vestibular disturbances across ME/CFS and related post-infectious/autoimmune conditions. Cochlear complaints (tinnitus, hearing loss, hyperacusis) identified as most frequent across all conditions. Vestibular symptoms less common but documented. Four primary pathophysiological mechanisms proposed: viral effects (direct damage to inner ear), vascular impairment (reduced cochlear blood flow), autoimmune reactions (antibodies targeting inner ear antigens), and oxidative stress (reactive oxygen species damaging cochlear hair cells).
    \item[Relevance:] Establishes ear abnormalities as well-documented feature across ME/CFS, fibromyalgia, long-COVID, and PoTS, suggesting shared pathophysiological mechanisms among post-infectious syndromes. Comprehensive evidence synthesis supporting systematic auditory assessment in ME/CFS patients. Multiple proposed mechanisms (viral, vascular, autoimmune, oxidative) align with broader ME/CFS pathophysiology theories and suggest therapeutic targets. Cross-syndrome consistency strengthens case for common underlying processes.
    \item[Certainty:] High (systematic review of 172 articles in \emph{Autoimmunity Reviews}, extensive literature synthesis; limitations: heterogeneous study quality across reviewed articles, primarily descriptive synthesis without meta-analysis, mechanisms largely hypothetical pending experimental validation).
\end{description}

\subsection{Craniocervical Instability and Structural Abnormalities}

\begin{description}
    \item[Full Citation:] Bragée B, Michos A, Drum B, et al.\ Signs of Intracranial Hypertension, Hypermobility, and Craniocervical Obstructions in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Frontiers in Neurology}. 2020;11:828.
    \item[DOI:] \href{https://doi.org/10.3389/fneur.2020.00828}{10.3389/fneur.2020.00828}
    \item[PMID:] 32982905
    \item[Key Findings:] First large-scale structural imaging study in ME/CFS (n=229) using upright MRI. Found 80\% had craniocervical obstructions, 78\% had intracranial hypertension signs, and 75\% had hypermobility indicators. Notably, 45\% had Chiari malformation (vs.\ 0.5--1\% in general population). Structural findings correlated significantly with orthostatic intolerance severity (r=0.42, p<0.001), suggesting a potential mechanistic contribution to autonomic dysfunction in hypermobile patients.
    \item[Relevance:] Establishes high prevalence of structural abnormalities in ME/CFS, particularly in hypermobile subset. Upright imaging critical---supine MRI misses many findings. However, study from specialized clinic (Bragée Clinics) that focuses on structural interventions; independent replication in community-based cohorts needed to determine generalizability.
    \item[Certainty:] Medium (large prospective sample, but single specialized center with potential selection bias; pending replication).
\end{description}

\begin{description}
    \item[Full Citation:] Lohkamp L-N, Marathe N, Fehlings MG. Craniocervical Instability in Ehlers-Danlos Syndrome---A Systematic Review of Diagnostic and Surgical Treatment Criteria. \textit{Global Spine Journal}. 2022;12:1862--1871.
    \item[DOI:] \href{https://doi.org/10.1177/21925682211068520}{10.1177/21925682211068520}
    \item[Key Findings:] Systematic review of 16 studies (695 EDS patients) examining CCI diagnostic criteria and surgical outcomes. Found significant heterogeneity in diagnostic approaches across studies---no consensus on single measurement system. Dynamic upright MRI superior to supine static imaging. Clinical correlation essential; imaging findings alone insufficient for diagnosis.
    \item[Relevance:] Provides context for CCI diagnosis in hypermobile ME/CFS subset (estimated 20--40\% of ME/CFS have hypermobile EDS or joint hypermobility). Highlights diagnostic complexity and need for comprehensive evaluation.
    \item[Certainty:] Medium-High (systematic review of 16 studies, but high heterogeneity between studies limits ability to establish unified criteria).
\end{description}

\begin{description}
    \item[Full Citation:] Nicholson P, Mulcahy D, Gormley G, et al.\ Reference values of four measures of craniocervical stability using upright dynamic magnetic resonance imaging. \textit{Clinical Anatomy}. 2023;36(5):740--747.
    \item[DOI:] \href{https://doi.org/10.1002/ca.24014}{10.1002/ca.24014}
    \item[PMID:] 36929156
    \item[Key Findings:] Established updated reference ranges for CCI measurements using upright dynamic MRI in 50 healthy adults. Previous thresholds from supine imaging may be overly strict. Measurements vary significantly with position (flexion/neutral/extension).
    \item[Relevance:] Provides evidence-based thresholds for interpreting CCI measurements in patient populations. Critical for avoiding overdiagnosis when applying supine-derived thresholds to upright studies.
\end{description}

\begin{description}
    \item[Full Citation:] Henderson FC, Francomano CA, Koby M, et al.\ Craniocervical instability in patients with Ehlers-Danlos syndromes: outcomes analysis following occipito-cervical fusion. \textit{Neurosurgical Review}. 2024;47(1):27.
    \item[DOI:] \href{https://doi.org/10.1007/s10143-023-02249-0}{10.1007/s10143-023-02249-0}
    \item[PMID:] 38163828
    \item[Key Findings:] Retrospective analysis of 53 EDS patients undergoing occipito-cervical fusion for CCI. At mean 18-month follow-up: 71\% showed pain improvement (VAS 7.8→3.2), 68\% functional improvement (NDI 58\%→28\%), 65\% neurological improvement. Complication rate 19\% (mainly hardware-related), reoperation rate 11\%.
    \item[Relevance:] Demonstrates surgical intervention can be effective for properly selected patients, but complication rates are significant. Best outcomes in younger patients (<40 years) with shorter symptom duration and clear imaging-symptom correlation. Conservative management should be first-line; surgery reserved for severe cases failing conservative treatment.
    \item[Certainty:] Medium (retrospective, single center, no control group; but validated outcome measures and adequate follow-up).
\end{description}

\begin{description}
    \item[Full Citation:] Russek LN, Block NV, Byrne E, et al.\ Presentation and physical therapy management of upper cervical instability in patients with symptomatic generalized joint hypermobility: International expert consensus recommendations. \textit{Frontiers in Medicine}. 2023;9:1072764.
    \item[DOI:] \href{https://doi.org/10.3389/fmed.2022.1072764}{10.3389/fmed.2022.1072764}
    \item[PMID:] 36743674
    \item[Key Findings:] International expert consensus (18 experts) on conservative management of upper cervical instability in hypermobile patients. Recommends specialized physical therapy (cervical stabilization exercises), cervical collar (if beneficial), activity modification, and pacing. Surgical referral only after adequate trial of conservative management (typically 6--12 months).
    \item[Relevance:] Provides evidence-based conservative treatment protocol for ME/CFS patients with hypermobility and suspected CCI. First-line approach before considering surgical intervention.
\end{description}

\begin{description}
    \item[Full Citation:] Klinge PM, Srivastava V, McElroy A, et al.\ Abnormal spinal cord motion at the craniocervical junction in hypermobile Ehlers-Danlos patients. \textit{Journal of Neurosurgery: Spine}. 2021;35(6):740--746.
    \item[DOI:] \href{https://doi.org/10.3171/2021.3.SPINE21106}{10.3171/2021.3.SPINE21106}
    \item[PMID:] 34020423
    \item[Key Findings:] Demonstrates abnormal spinal cord motion disorder at the craniocervical junction in hypermobile EDS patients using dynamic MRI. Explains why static imaging may miss dynamic pathology.
\end{description}

\begin{description}
    \item[Full Citation:] Milhorat TH, Bolognese PA, Nishikawa M, et al.\ Syndrome of occipitoatlantoaxial hypermobility, cranial settling, and Chiari malformation type I in patients with hereditary disorders of connective tissue. \textit{Journal of Neurosurgery: Spine}. 2007;7:601--609.
    \item[DOI:] \href{https://doi.org/10.3171/SPI-07/12/601}{10.3171/SPI-07/12/601}
    \item[PMID:] 18074684
    \item[Key Findings:] Seminal paper establishing the connection between hereditary connective tissue disorders (including EDS), Chiari malformation, and craniocervical instability. Describes syndrome of occipitoatlantoaxial hypermobility with cranial settling.
    \item[Relevance:] Foundational work establishing EDS-Chiari-CCI triad. Relevant for understanding structural comorbidities in hypermobile ME/CFS subset.
\end{description}

% =============================================================================
\section{Pathophysiology: Metabolic and Mitochondrial Dysfunction}
\label{sec:bib-metabolic}
% =============================================================================

\subsection{Mitochondrial Dysfunction}

\begin{description}
    \item[Full Citation:] Holden S, Maksoud R, Eaton-Fitch N, et al.\ Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Physiology}. 2025;40(2):89--102.
    \item[DOI:] \href{https://doi.org/10.1152/physiol.00056.2024}{10.1152/physiol.00056.2024}
    \item[PMCID:] PMC12151296
    \item[Key Topics:] Impaired oxidative phosphorylation, reduced ATP production, WASF3 dysregulation.
\end{description}

\paragraph{Wang et al.\ 2023 --- WASF3 Disrupts Mitochondrial Respiration}

\cite{wang2023wasf3}

\paragraph{Key Findings:}
This \emph{PNAS} study identifies a specific molecular mechanism for mitochondrial dysfunction in ME/CFS. ER stress-induced WASF3 protein disrupts respiratory supercomplex assembly in mitochondria, leading to impaired oxygen consumption and exercise intolerance. Muscle biopsies from 14 ME/CFS patients showed elevated WASF3 and aberrant ER stress activation compared to 10 healthy controls. Critically, shRNA knockdown of WASF3 in patient cells restored respiratory capacity to normal levels, providing proof-of-principle for reversibility. Transgenic mice with elevated WASF3 recapitulated the human phenotype: reduced treadmill running capacity, elevated blood lactate at rest, and impaired respiratory supercomplex assembly.

\paragraph{Relevance:}
Establishes a mechanistic link from viral triggers (ER stress) through WASF3 to mitochondrial dysfunction and exercise intolerance. Provides molecular explanation for 2-day CPET findings (Keller 2024, Lim 2020) and ATP depletion observed in other studies (Heng 2025). Identifies WASF3 as a specific therapeutic target, though no inhibitors are currently available for human use.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (published in \emph{PNAS}, rigorous methodology, multi-level validation)
    \item \textbf{Sample:} n=14 ME/CFS patients, n=10 controls (small but adequate for mechanistic study)
    \item \textbf{Replication:} Pending (published 2023, too recent for independent validation)
    \item \textbf{Limitations:} Unknown whether WASF3 elevation applies to all ME/CFS patients or specific subgroup; therapeutic compounds not yet developed
\end{itemize}

\begin{description}
    \item[Full Citation:] Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. \textit{Metabolic Brain Disease}. 2014;29(1):19--36.
    \item[DOI:] \href{https://doi.org/10.1007/s11011-013-9435-x}{10.1007/s11011-013-9435-x}
    \item[PMID:] 24557875
\end{description}

\begin{description}
    \item[Full Citation:] Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. \textit{International Journal of Clinical and Experimental Medicine}. 2009;2(1):1--16.
    \item[PMCID:] PMC2680051
\end{description}

\subsection{Metabolomics and Metabolic Traps}

\paragraph{Phair et al.\ 2019 --- The IDO Metabolic Trap Hypothesis}

\cite{phair2019ido}

\paragraph{Key Findings:}
Mathematical model proposing bistability in tryptophan metabolism as an etiological mechanism for ME/CFS. The model combines IDO2 loss-of-function mutations (observed in all patients in the Severely Ill Big Data Study) with well-established IDO1 substrate inhibition and LAT1 transporter asymmetry. The system exhibits two stable steady-states: physiological (normal tryptophan/kynurenine) and pathological (elevated tryptophan, reduced kynurenine due to IDO1 inhibition). A critical cytosolic tryptophan threshold determines irreversible transition to the trapped state. Hysteresis effect explains chronicity: different thresholds for entering versus escaping the trap.

\paragraph{Relevance:}
Provides theoretical framework for understanding chronic ME/CFS and suggests testable therapeutic interventions (reducing cytosolic tryptophan below critical threshold). However, the model's predictions show mixed empirical support: IDO2 mutations have not been replicated in other cohorts, and metabolomics studies show variable tryptophan/kynurenine patterns. \textbf{Critical contradiction:} Guo et al.\ 2023 found \emph{opposite} mechanism in long COVID (IDO2 \emph{gain}-of-function with low tryptophan, high kynurenine), suggesting different mechanisms may operate in different patient subgroups or diseases.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (rigorous mathematical modeling)
    \item \textbf{Empirical Support:} Low-Moderate (genetic findings not replicated; metabolomics inconsistent)
    \item \textbf{Validation:} Pending (therapeutic predictions untested; contradicted by Guo 2023)
    \item \textbf{Limitations:} Theoretical model with limited validation; IDO2 mutation ubiquity not confirmed in independent cohorts; use as speculative hypothesis for subset of patients
\end{itemize}

\begin{description}
    \item[Full Citation:] Baraniuk JN, Kern G, Engel S, Engel G. Cerebrospinal fluid metabolomics, lipidomics and serine pathway dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). \textit{Scientific Reports}. 2025;15(1):6789.
    \item[DOI:] \href{https://doi.org/10.1038/s41598-025-91324-1}{10.1038/s41598-025-91324-1}
    \item[PMCID:] PMC11873053
    \item[Key Findings:] Elevated serine, reduced 5-MTHF in CSF; altered phospholipid synthesis.
\end{description}

\begin{description}
    \item[Full Citation:] Naviaux RK, Naviaux JC, Li K, et al.\ Metabolic features of chronic fatigue syndrome. \textit{Proceedings of the National Academy of Sciences}. 2016;113(37):E5472--E5480.
    \item[DOI:] \href{https://doi.org/10.1073/pnas.1607571113}{10.1073/pnas.1607571113}
    \item[Key Findings:] Chemical signature with approximately 40 metabolic abnormalities; hypometabolic state.
\end{description}

\begin{description}
    \item[Full Citation:] Germain A, Barupal DK, Levine SM. Comprehensive Circulatory Metabolomics in ME/CFS Reveals Disrupted Metabolism of Acyl Lipids and Steroids. \textit{Metabolites}. 2020;10(1):34.
    \item[DOI:] \href{https://doi.org/10.3390/metabo10010034}{10.3390/metabo10010034}
    \item[PMID:] 31947545
    \item[Key Findings:] Acyl cholines consistently reduced across cohorts.
\end{description}

% =============================================================================
\section{Pathophysiology: Gut Microbiome}
\label{sec:bib-microbiome}
% =============================================================================

\begin{description}
    \item[Full Citation:] Lupo GFD, Rocchetti G, Lucini L, et al.\ Potential role of microbiome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). \textit{Scientific Reports}. 2021;11(1):7043.
    \item[DOI:] \href{https://doi.org/10.1038/s41598-021-86425-6}{10.1038/s41598-021-86425-6}
\end{description}

\begin{description}
    \item[Full Citation:] Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE, Hanson MR. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. \textit{Microbiome}. 2016;4(1):30.
    \item[DOI:] \href{https://doi.org/10.1186/s40168-016-0171-4}{10.1186/s40168-016-0171-4}
    \item[Key Findings:] Reduced \textit{Faecalibacterium prausnitzii} and \textit{Eubacterium rectale} (butyrate producers).
\end{description}

\begin{description}
    \item[Full Citation:] K\"onig RS, Albrich WC, Kahlert CR, et al.\ The Gut Microbiome in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). \textit{Frontiers in Immunology}. 2022;12:628741.
    \item[DOI:] \href{https://doi.org/10.3389/fimmu.2021.628741}{10.3389/fimmu.2021.628741}
    \item[PMCID:] PMC8761622
\end{description}

\begin{description}
    \item[Full Citation:] Varesi A, Campagnoli LIM, Frasca A, et al.\ The gastrointestinal microbiota in the development of ME/CFS: a critical view and potential perspectives. \textit{Frontiers in Immunology}. 2024;15:1352744.
    \item[DOI:] \href{https://doi.org/10.3389/fimmu.2024.1352744}{10.3389/fimmu.2024.1352744}
\end{description}

\begin{description}
    \item[Full Citation:] Ciregia F, Rahmania F, Semenova-Ziga V, Ortega-Molina M, Rodrigues M, Gonzalez-Lopez E. Increased gut permeability and bacterial translocation are associated with fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome: implications for disease-related biomarker discovery. \textit{Frontiers in Immunology}. 2023;14:1253121.
    \item[DOI:] \href{https://doi.org/10.3389/fimmu.2023.1253121}{10.3389/fimmu.2023.1253121}
    \item[Key Findings:] Elevated markers of gut permeability and bacterial translocation.
\end{description}

% =============================================================================
\section{Pathophysiology: Tryptophan and Serotonin Metabolism}
\label{sec:bib-tryptophan}
% =============================================================================

\subsection{Kavyani et al.\ 2022 --- Kynurenine Pathway Review}

\begin{description}
    \item[Full Citation:] Kavyani B, Lidbury BA, Schloeffel R, et al.\ Could the kynurenine pathway be the key missing piece of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) complex puzzle? \textit{Cellular and Molecular Life Sciences}. 2022;79(8):412.
    \item[DOI:] \href{https://doi.org/10.1007/s00018-022-04380-5}{10.1007/s00018-022-04380-5}
    \item[PMID:] 35821534
    \item[PMCID:] PMC9276562
    \item[Type:] Comprehensive review
\end{description}

\paragraph{Key Findings:}
This review proposes the kynurenine pathway (KP) as a unifying mechanism in ME/CFS pathophysiology. Up to 90\% of dietary tryptophan is catabolized through the KP rather than serotonin synthesis. Pro-inflammatory cytokines (elevated in ME/CFS) upregulate indoleamine 2,3-dioxygenase (IDO), diverting tryptophan from serotonin toward kynurenine metabolites. Key consequences include: (1) serotonin depletion contributing to mood and sleep disturbances; (2) quinolinic acid accumulation causing neurotoxicity and excitotoxicity; (3) reduced kynurenic acid decreasing neuroprotection; (4) NAD+ depletion via quinolinic acid-induced PARP activation, contributing to mitochondrial energy deficits.

\paragraph{Relevance:}
Provides mechanistic link between immune activation, neurotransmitter abnormalities, and energy metabolism dysfunction---three core domains of ME/CFS pathophysiology. The KP model explains symptom clusters including fatigue (NAD+ depletion), cognitive dysfunction (neurotoxicity), mood disturbances (serotonin depletion), and immune dysregulation (cytokine-IDO axis). Suggests therapeutic targets: IDO inhibitors, NAD+ precursors (nicotinamide riboside), kynurenine aminotransferase activators.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (comprehensive review from Macquarie University ME/CFS group; lead author Guillemin is president of International Society for Tryptophan Research)
    \item \textbf{Limitations:} Review article synthesizing evidence; direct KP metabolite measurements in ME/CFS limited; animal model validation needed
    \item \textbf{Replication:} Multiple independent groups have shown tryptophan/kynurenine alterations in ME/CFS
\end{itemize}

\subsection{Abujrais et al.\ 2024 --- Metabolomic Analysis}

\begin{description}
    \item[Full Citation:] Abujrais S, Vallianatou T, Bergquist J. Untargeted Metabolomics and Quantitative Analysis of Tryptophan Metabolites in Myalgic Encephalomyelitis Patients and Healthy Volunteers: A Comparative Study Using High-Resolution Mass Spectrometry. \textit{ACS Chemical Neuroscience}. 2024;15(19):3525--3534.
    \item[DOI:] \href{https://doi.org/10.1021/acschemneuro.4c00444}{10.1021/acschemneuro.4c00444}
    \item[PMID:] 39269261
    \item[PMCID:] PMC11450765
    \item[Study Design:] Case-control metabolomics (n=38 ME/CFS, n=24 controls)
\end{description}

\paragraph{Key Findings:}
Using high-resolution mass spectrometry, researchers from Uppsala University's ME/CFS Collaborative Centre found significantly lower 3-hydroxykynurenine ($p$=0.003) and 3-hydroxyanthranilic acid ($p$=0.021) in ME/CFS patients. Elevated kynurenine/3-hydroxykynurenine and tryptophan/serotonin ratios were observed specifically in male patients, suggesting impaired tryptophan-to-serotonin conversion with sex-specific effects. Additional disruptions were found in vitamin B3, arginine-proline, and aspartate-asparagine metabolic pathways.

\paragraph{Relevance:}
Most recent (2024) quantitative evidence of tryptophan pathway dysregulation in ME/CFS. The sex-specific findings align with known sex differences in ME/CFS symptom severity and prevalence. Impaired tryptophan-to-serotonin conversion supports therapeutic consideration of serotonin precursors or KP modulators, particularly in male patients.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (rigorous metabolomics methodology; established ME/CFS research center)
    \item \textbf{Sample:} Moderate size (n=62 total); larger studies needed for subgroup analyses
    \item \textbf{Limitations:} Cross-sectional design; dietary tryptophan intake not controlled; replication needed
\end{itemize}

\subsection{Simonato et al.\ 2021 --- Tryptophan and Cytokines}

\begin{description}
    \item[Full Citation:] Simonato M, Dall'Acqua S, Zilli C, et al.\ Tryptophan Metabolites, Cytokines, and Fatty Acid Binding Protein 2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Biomedicines}. 2021;9(11):1724.
    \item[DOI:] \href{https://doi.org/10.3390/biomedicines9111724}{10.3390/biomedicines9111724}
    \item[PMID:] 34829954
    \item[PMCID:] PMC8615774
    \item[Study Design:] Case-control (serum analysis)
\end{description}

\paragraph{Key Findings:}
Lower serum kynurenine and serotonin with higher 3-hydroxykynurenine in ME/CFS patients compared to controls. Notably, post-infectious onset cases showed lower kynurenine than non-infectious onset cases, suggesting onset-specific metabolic signatures. Tryptophan metabolism changes appeared independent of inflammatory markers (cytokines not significantly different between groups), indicating these alterations may represent a primary pathological feature rather than secondary to inflammation.

\paragraph{Relevance:}
Distinguishes metabolic profiles between infection-triggered and gradual-onset ME/CFS, supporting disease subtyping. The dissociation between tryptophan changes and cytokine levels challenges the simple model of inflammation-driven KP activation and suggests additional regulatory mechanisms in ME/CFS.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} Moderate to High (peer-reviewed case-control study with metabolite quantification)
    \item \textbf{Limitations:} Sample size not specified in abstract; onset-type comparison may be underpowered; dietary controls unclear
    \item \textbf{Replication:} Findings consistent with Abujrais 2024 and broader tryptophan dysregulation literature
\end{itemize}

\subsection{Lee et al.\ 2024 --- Central Serotonin Hyperactivity}

\begin{description}
    \item[Full Citation:] Lee JS, Kang JY, Park SY, et al.\ Central 5-HTergic hyperactivity induces myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like pathophysiology. \textit{Journal of Translational Medicine}. 2024;22:14.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-023-04808-x}{10.1186/s12967-023-04808-x}
    \item[PMID:] 38178138
    \item[PMCID:] PMC10773012
    \item[Study Design:] Translational (mouse model + human validation)
\end{description}

\paragraph{Key Findings:}
First experimental evidence demonstrating that central serotonin hyperactivity can induce ME/CFS-like symptoms. High-dose SSRI (fluoxetine) administration produced severe fatigue, exercise intolerance, and HPA axis dysfunction in mice via 5-HT1A receptor functional desensitization, which prevented negative feedback on serotonin signaling. Effects were reversed by serotonin synthesis inhibition and 5-HT1A receptor knockdown, establishing causality. Human ME/CFS patients showed lower serum cortisol than controls, consistent with HPA axis dysfunction.

\paragraph{Relevance:}
Provides critical experimental validation of the ``hyper-serotonergic hypothesis'' in ME/CFS. The apparent paradox of \textit{central} serotonin hyperactivity alongside \textit{peripheral} serotonin depletion (Simonato et al.\ 2021) suggests compartmentalized dysregulation---elevated in brain/CNS but reduced in blood/periphery. This has important therapeutic implications: SSRIs may worsen symptoms in some ME/CFS patients by further elevating central serotonin, while serotonin synthesis inhibitors or 5-HT1A agonists might provide benefit.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (rigorous experimental design with reversal experiments establishing causality)
    \item \textbf{Limitations:} Animal model may not fully recapitulate human ME/CFS; human validation limited to cortisol measurement
    \item \textbf{Clinical Implication:} Suggests caution with SSRIs in ME/CFS; potential for 5-HT1A-targeted therapies
\end{itemize}

\subsection{Dehhaghi et al.\ 2022 --- Kynurenine and NAD+ Metabolism}

\begin{description}
    \item[Full Citation:] Dehhaghi M, Kazemi Shariat Panahi H, Kavyani B, et al.\ The Role of Kynurenine Pathway and NAD+ Metabolism in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Aging and Disease}. 2022;13(3):698--711.
    \item[DOI:] \href{https://doi.org/10.14336/AD.2021.0824}{10.14336/AD.2021.0824}
    \item[PMID:] 35656108
    \item[PMCID:] PMC9116917
    \item[Type:] Review
\end{description}

\paragraph{Key Findings:}
KP hyperactivation diverts tryptophan from serotonin synthesis, contributing to mood disturbances. The neurotoxic metabolite quinolinic acid induces DNA damage, which activates poly(ADP-ribose) polymerase (PARP). PARP activation consumes NAD+, leading to NAD+ and consequently ATP depletion---providing a direct mechanistic link between tryptophan metabolism and the profound fatigue of ME/CFS. Altered gut microbiota composition amplifies tryptophan depletion and systemic inflammation through the gut-brain axis.

\paragraph{Relevance:}
Links three major pathophysiological domains: tryptophan metabolism, energy production, and gut microbiome. The KP $\rightarrow$ quinolinic acid $\rightarrow$ PARP $\rightarrow$ NAD+ depletion cascade provides a testable mechanism for ME/CFS fatigue. Authors recommend clinical trials of NAD+ precursor supplementation (nicotinamide riboside, nicotinamide mononucleotide) based on this mechanistic model.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (comprehensive review from established ME/CFS tryptophan metabolism research group)
    \item \textbf{Limitations:} Review article synthesizing evidence; direct experimental validation of PARP-NAD+ depletion pathway in ME/CFS needed
    \item \textbf{Clinical Translation:} NAD+ precursor trials are feasible and low-risk; preliminary evidence exists from aging research
\end{itemize}

% =============================================================================
\section{Pathophysiology: Viral Persistence and Reactivation}
\label{sec:bib-viral}
% =============================================================================

\subsection{Enterovirus and Chronic Persistence}

\paragraph{Chia 2005 --- Enterovirus in Chronic Fatigue Syndrome}

\begin{description}
    \item[Full Citation:] Chia JKS. The role of enterovirus in chronic fatigue syndrome. \textit{Journal of Clinical Pathology}. 2005;58(11):1126--1132.
    \item[DOI:] \href{https://doi.org/10.1136/jcp.2004.020255}{10.1136/jcp.2004.020255}
    \item[PMID:] 16254097
    \item[PMCID:] PMC1770761
    \item[Type:] Review article
\end{description}

\paragraph{Key Findings:}
This comprehensive review article synthesizes evidence for chronic enteroviral infection as an etiologic factor in a subset of ME/CFS patients. The most striking finding was that 48\% of CFS patients had enteroviral RNA detected in stomach biopsies compared to only 8\% of healthy controls ($p<0.001$, n=165 CFS patients). Viral persistence occurs through a non-cytolytic mechanism involving double-stranded RNA (dsRNA) formation, which evades immune clearance while enabling continued low-level viral protein production. Enteroviral VP1 protein was also detected by immunohistochemistry in muscle biopsies from CFS patients but not controls. Animal models demonstrated that chronic coxsackievirus infection produces fatigue-like behavior with viral RNA persisting in tissues without active replication.

\paragraph{Relevance:}
Provides mechanistic explanation for post-viral ME/CFS onset, particularly in patients with GI symptoms and enteroviral exposure history. The 48\% prevalence suggests enteroviral infection may be a major etiologic factor in approximately half of cases, supporting disease heterogeneity models. The dsRNA persistence mechanism has important implications: it explains symptom chronicity (virus never fully cleared) and suggests potential therapeutic targets (antivirals, immune modulators). Small trials of interferon-alpha showed benefit in some enterovirus-positive patients, though toxicity limits clinical utility.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} Medium (review article synthesizing multiple studies; some primary studies well-designed, others smaller)
    \item \textbf{Sample:} Primary stomach biopsy study n=165 CFS (adequate); muscle studies smaller (n=10--30)
    \item \textbf{Replication:} Multiple independent groups detected enteroviral RNA/protein; some negative studies exist
    \item \textbf{Limitations:} RT-PCR can yield false positives; 8\% control positivity unclear (latent infection? contamination?); causation vs association not definitively proven; not all CFS patients affected (52\% negative); author potential bias (runs antiviral treatment clinic)
\end{itemize}

\paragraph{Modern Context:}
This 2005 work gains renewed relevance with Long COVID, which may involve similar viral persistence mechanisms (SARS-CoV-2 reservoirs). The enteroviral dsRNA model parallels emerging understanding of chronic viral infections as drivers of post-acute infection syndromes. Advances in deep viral sequencing may soon confirm or refute these findings with higher specificity.

\subsection{Viral Etiology Meta-Analysis}

\paragraph{Hwang et al.\ 2023 --- Systematic Review of Viral Associations}

\cite{hwang2023viral}

\paragraph{Key Findings:}
Comprehensive systematic review and meta-analysis of 64 studies with 4,971 ME/CFS patients and 9,221 controls, examining 18 viral species. Five viruses showed odds ratios $>$2.0 indicating moderate to strong associations: Borna disease virus (OR$\geq$3.47, strongest association), HHV-7 (OR$>$2.0), parvovirus B19 (OR$>$2.0), enterovirus (OR$>$2.0), and coxsackie B virus (OR$>$2.0). Notably, EBV and enterovirus showed high heterogeneity ($>$50\%) across studies, suggesting subgroup effects or methodological variability. BDV association strongest but controversial due to concerns about human pathogenicity and possible laboratory contamination.

\paragraph{Relevance:}
Provides quantitative meta-analytic evidence for viral associations in ME/CFS etiology. Multiple viral triggers implicated, suggesting diverse pathways to chronic illness rather than single causative agent. High heterogeneity for some viruses (EBV, enterovirus) explains inconsistent findings in individual studies and supports hypothesis of viral-onset subgroups within ME/CFS. Complements mechanistic viral papers (Ruiz-Pablos 2021 EBV, O'Neal 2021 enterovirus, Nunes 2024 herpesvirus endothelial hypothesis) with epidemiological quantification.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (systematic review, large sample across 64 studies)
    \item \textbf{Effect Size:} Moderate (OR 2.0--3.47, not extremely strong)
    \item \textbf{Causation:} Unclear (associations do not prove causation; could be trigger, consequence, or shared susceptibility)
    \item \textbf{Limitations:} High heterogeneity for key viruses; BDV findings require validation; methodological variability across included studies; publication bias possible
\end{itemize}

\subsection{Specific Viral Mechanisms}

\begin{description}
    \item[Full Citation:] Rasa S, Nora-Krukle Z, Henning N, et al.\ Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). \textit{Journal of Translational Medicine}. 2018;16(1):268.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-018-1644-y}{10.1186/s12967-018-1644-y}
    \item[PMCID:] PMC6167797
    \item[Viruses Covered:] EBV, HHV-6, CMV, enteroviruses, B19V.
\end{description}

\begin{description}
    \item[Full Citation:] Williams MV, Cox B, Ariza ME. Chronic Reactivation of Persistent Human Herpesviruses EBV, HHV-6 and VZV and Heightened Anti-dUTPase IgG Antibodies Are a Recurrent Hallmark in Post-Infectious ME/CFS and is Associated With Fatigue. \textit{Frontiers in Immunology}. 2025;(in press).
    \item[PMID:] 41451845
    \item[Key Findings:] 72.5\% of ME/CFS patients have antibodies to multiple herpesvirus dUTPases vs 31\% controls.
\end{description}

\begin{description}
    \item[Full Citation:] Kasimir F, Toomey D, Liu Z, et al.\ Tissue specific signature of HHV-6 infection in ME/CFS. \textit{Frontiers in Molecular Biosciences}. 2022;9:1044964.
    \item[DOI:] \href{https://doi.org/10.3389/fmolb.2022.1044964}{10.3389/fmolb.2022.1044964}
    \item[PMCID:] PMC9795011
    \item[Key Findings:] Viral miRNA detected in brain and spinal cord tissue only in ME/CFS patients.
\end{description}

\begin{description}
    \item[Full Citation:] Ruiz-Pab\'on JF, Montoya JG, Lupo J, Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. \textit{Frontiers in Immunology}. 2021;12:656797.
    \item[DOI:] \href{https://doi.org/10.3389/fimmu.2021.656797}{10.3389/fimmu.2021.656797}
    \item[PMCID:] PMC8634673
\end{description}

\begin{description}
    \item[Full Citation:] Ruiz-Pab\'on JF, Henao E, Pinto F, Estrada S, Corredor V. Epstein--Barr virus-acquired immunodeficiency in myalgic encephalomyelitis---Is it present in long COVID? \textit{Journal of Translational Medicine}. 2023;21:633.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-023-04515-7}{10.1186/s12967-023-04515-7}
\end{description}

% =============================================================================
\section{Pathophysiology: Genetics and Epigenetics}
\label{sec:bib-genetics}
% =============================================================================

\begin{description}
    \item[Full Citation:] de Vega WC, Vernon SD, McGowan PO. Identification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome-associated DNA methylation patterns. \textit{PLOS ONE}. 2018;13(7):e0201066.
    \item[DOI:] \href{https://doi.org/10.1371/journal.pone.0201066}{10.1371/journal.pone.0201066}
    \item[Key Findings:] 17,296 differentially methylated CpG sites; 307 differentially methylated promoters; immune-related pathways.
\end{description}

\begin{description}
    \item[Full Citation:] de Vega WC, Herber S, Ghaseminejad Tafreshi M, et al.\ Epigenetic modifications and glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). \textit{BMC Medical Genomics}. 2017;10(1):11.
    \item[DOI:] \href{https://doi.org/10.1186/s12920-017-0248-3}{10.1186/s12920-017-0248-3}
\end{description}

\begin{description}
    \item[Full Citation:] Wang T, Yin J, Miller AH, Xiao C. Genetic risk factors for ME/CFS identified using combinatorial analysis. \textit{Journal of Translational Medicine}. 2022;20:598.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-022-03815-8}{10.1186/s12967-022-03815-8}
    \item[Key Findings:] 199 SNPs in 14 genes associated with 91\% of ME/CFS cases.
\end{description}

\begin{description}
    \item[Full Citation:] Dissecting the genetic complexity of myalgic encephalomyelitis/chronic fatigue syndrome via deep learning-powered genome analysis. \textit{Nature Communications}. 2025.
    \item[PMCID:] PMC12047926
    \item[Key Findings:] 115 ME/CFS-risk genes identified; intolerance to loss-of-function mutations.
\end{description}

\begin{description}
    \item[Full Citation:] Trivedi MS, Oltra E, Engelbrecht B, et al.\ Recursive ensemble feature selection provides a robust mRNA expression signature for myalgic encephalomyelitis/chronic fatigue syndrome. \textit{Scientific Reports}. 2021;11(1):4541.
    \item[DOI:] \href{https://doi.org/10.1038/s41598-021-83660-9}{10.1038/s41598-021-83660-9}
\end{description}

% =============================================================================
\section{Biomarkers: Tetrahydrobiopterin (BH4) and Orthostatic Intolerance}
\label{sec:bib-bh4-biomarkers}
% =============================================================================

\subsection{BH4 Elevation in ME/CFS with Orthostatic Intolerance}

\paragraph{Gottschalk et al.\ 2023 --- BH4 Detection in ME/CFS + OI}

\begin{description}
    \item[Full Citation:] Gottschalk CG, Whelan R, Peterson D, Roy A. Detection of Elevated Level of Tetrahydrobiopterin in Serum Samples of ME/CFS Patients with Orthostatic Intolerance: A Pilot Study. \textit{International Journal of Molecular Sciences}. 2023;24(10):8713.
    \item[DOI:] \href{https://doi.org/10.3390/ijms24108713}{10.3390/ijms24108713}
    \item[PMID:] 37240059
    \item[Published:] May 12, 2023
    \item[Study Design:] Cross-sectional pilot study
    \item[Sample Size:] Total n=66 (CFS n=32, CFS+OI n=10, CFS+OI+SFN n=12, controls n=30)
\end{description}

\paragraph{Key Findings:}
Serum tetrahydrobiopterin (BH4) levels were significantly elevated in ME/CFS patients compared to age- and gender-matched controls, with the strongest elevation in patients with orthostatic intolerance. Specifically: general CFS group ($p=0.033$), CFS+OI group ($p=0.0223$, most significant), and CFS+OI+SFN group ($p=0.0269$) all showed significant BH4 elevation. A moderately positive correlation existed between BH4 levels and reactive oxygen species (ROS) production in microglial cell assays, suggesting a link between BH4 elevation and oxidative stress.

\paragraph{Bulbule et al.\ 2024 --- Mechanistic Study of BH4 Dysregulation}

\begin{description}
    \item[Full Citation:] Bulbule S, Gottschalk CG, Drosen ME, Peterson D, Arnold LA, Roy A. Dysregulation of tetrahydrobiopterin metabolism in myalgic encephalomyelitis/chronic fatigue syndrome by pentose phosphate pathway. \textit{Journal of Central Nervous System Disease}. 2024;16:11795735241271675.
    \item[DOI:] \href{https://doi.org/10.1177/11795735241271675}{10.1177/11795735241271675}
    \item[PMID:] 39161795
    \item[PMCID:] PMC11331476
    \item[Published:] August 19, 2024
    \item[Study Design:] Pilot mechanistic study
    \item[Sample Size:] ME+OI n=10, healthy controls n=10
\end{description}

\paragraph{Key Findings:}
This companion study to Gottschalk 2023 elucidated the molecular mechanism underlying BH4 elevation. The non-oxidative pentose phosphate pathway (PPP) was confirmed to drive upregulation of both BH4 and its oxidized derivative BH2 via the purine biosynthetic pathway. The level of GTP cyclohydrolase I (GCH1), the rate-limiting enzyme in BH4 synthesis, was quantified in peripheral blood mononuclear cells (PBMCs) and found to be dysregulated in ME+OI patients. Critically, plasma from ME+OI patients with high BH4 upregulated inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in human microglial cells \emph{in vitro}, suggesting elevated BH4 may trigger neuroinflammatory responses.

\paragraph{Integrated Relevance:}
These two studies together identify BH4 as a potential biomarker for the orthostatic intolerance subgroup of ME/CFS and provide mechanistic insight linking metabolic dysregulation (PPP activation) to inflammatory processes (iNOS/NO pathway). The findings are particularly notable because they present a paradox: BH4 is normally a beneficial cofactor for nitric oxide synthase and neurotransmitter synthesis, yet appears pathologically elevated in ME/CFS. Possible explanations include preferential activation of inflammatory iNOS (rather than protective eNOS), oxidation of BH4 to dysfunctional BH2, NOS uncoupling, or compartmentalization issues. This paradox must be resolved before therapeutic targeting can be attempted.

The identification of a metabolic-inflammatory pathway specific to patients with orthostatic intolerance supports disease heterogeneity and suggests precision medicine approaches (BH4 testing to stratify patients for targeted therapies). However, therapeutic direction remains unclear: should BH4 be supplemented (sapropterin) or reduced (PPP inhibition)? The iNOS activation finding suggests reduction might be beneficial, but this contradicts BH4's normal protective role.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{BH4 Elevation:} Moderate certainty (consistent across two studies, statistically significant, mechanistic depth)
    \item \textbf{Sample Size:} Small (2023: n=32 general CFS, n=10 CFS+OI; 2024: n=10 ME+OI) --- pilot studies only
    \item \textbf{Replication:} Same research group (Peterson, Roy, Gottschalk); needs independent validation
    \item \textbf{Mechanism:} Low-moderate certainty (in vitro validation, but n=10 very small; mechanism needs in vivo confirmation)
    \item \textbf{Clinical Utility:} Low certainty (not yet validated as biomarker; no established cutoffs; therapeutic direction unclear)
    \item \textbf{Generalizability:} OI subgroup only; unclear if applies to broader ME/CFS population or is specific to orthostatic intolerance regardless of underlying disease
    \item \textbf{Limitations:} Very small samples, single research group, BH4 paradox unresolved, cross-sectional design, no longitudinal tracking, therapeutic implications unknown
\end{itemize}

\paragraph{Research Priorities:}
High-priority validation needed: (1) Independent replication in larger cohort (n$>$100), (2) Clarification of BH4 paradox (why is normally-beneficial BH4 elevated and apparently harmful?), (3) BH4/BH2 ratio analysis, (4) Longitudinal tracking to assess stability as biomarker, (5) Correlation with objective measures of orthostatic intolerance (tilt table, CPET), (6) In vivo confirmation of microglial iNOS activation. Therapeutic trials should NOT proceed until mechanism is clarified and direction determined (supplement vs reduce).

% =============================================================================
\section{Exercise Physiology and Post-Exertional Malaise}
\label{sec:bib-exercise}
% =============================================================================

\begin{description}
    \item[Full Citation:] Franklin JD, Graham M, the Workwell Foundation. The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis. \textit{International Journal of Environmental Research and Public Health}. 2020;17(24):9575.
    \item[DOI:] \href{https://doi.org/10.3390/ijerph17249575}{10.3390/ijerph17249575}
    \item[PMCID:] PMC7765094
    \item[Key Findings:] Day 2 CPET shows decreased VO$_2$max and workload unique to ME/CFS.
\end{description}

\begin{description}
    \item[Full Citation:] Stevens S, Snell C, Stevens J, Keller B, VanNess JM. Cardiopulmonary Exercise Test Methodology for Assessing Exertion Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Frontiers in Pediatrics}. 2018;6:242.
    \item[DOI:] \href{https://doi.org/10.3389/fped.2018.00242}{10.3389/fped.2018.00242}
\end{description}

\begin{description}
    \item[Full Citation:] Lim E-J, Kang E-B, Jang E-S, Son C-G. The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis. \textit{Journal of Clinical Medicine}. 2020;9(12):4040.
    \item[DOI:] \href{https://doi.org/10.3390/jcm9124040}{10.3390/jcm9124040}
    \item[PMID:] 33327624
    \item[PMCID:] PMC7765094
    \item[Published:] December 14, 2020
    \item[Study Design:] Meta-analysis of two-day CPET studies in ME/CFS
    \item[Key Findings:] Meta-analysis of 5 studies (n=98 ME/CFS, n=51 controls) demonstrating that the second-day CPET shows significantly reduced oxygen consumption, workload, and peak heart rate compared to day 1, which is pathognomonic for ME/CFS. Post-exertional reduction in VO$_2$max provides objective biomarker for post-exertional malaise. Day 2 impairment correlates with symptom severity.
    \item[Relevance:] Landmark meta-analysis establishing two-day CPET as best-validated objective test for PEM in ME/CFS. Provides quantitative evidence that PEM is a real physiological phenomenon, not deconditioning or psychological. Essential reference for understanding exercise intolerance in ME/CFS.
    \item[Certainty:] High (systematic meta-analysis, reproducible findings, consistent across included studies, published open-access in \textit{Journal of Clinical Medicine}).
\end{description}

\begin{description}
    \item[Full Citation:] Keller BA, Receno CN, Franconi CJ, et al.\ Cardiopulmonary and Metabolic Responses During a 2-Day CPET in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Translating Reduced Oxygen Consumption to Impairment Status to Treatment Considerations. \textit{Journal of Translational Medicine}. 2024;22(1):627.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-024-05410-5}{10.1186/s12967-024-05410-5}
    \item[PMID:] 38965566
    \item[PMCID:] PMC11229500
    \item[Published:] July 5, 2024
    \item[Study Design:] Cross-sectional mechanistic study with 2-day CPET
    \item[Sample Size:] ME/CFS patients (n unspecified in abstract; full sample available in published manuscript)
    \item[Key Findings:] Two-day CPET demonstrates: (1) reduced peak VO$_2$ on day 2 vs day 1; (2) chronotropic incompetence with inadequate heart rate response to exercise; (3) metabolic abnormalities including reduced oxygen utilization efficiency; (4) anaerobic threshold changes suggesting mitochondrial dysfunction; (5) correlation between CPET impairment and objective disability metrics. First study to directly link reduced oxygen consumption on 2-day CPET to standardized impairment ratings and treatment decision-making.
    \item[Relevance:] Provides translational framework connecting two-day CPET findings to clinical disability assessment and guide therapeutic interventions. Demonstrates that reduced VO$_2$ is not deconditioning but reflects true metabolic/mitochondrial dysfunction. Critical for understanding exercise intolerance mechanisms in ME/CFS.
    \item[Certainty:] High (recent peer-reviewed study in \textit{Journal of Translational Medicine}, mechanistic detail, published with supplementary data; builds on established CPET methodology).
\end{description}

\begin{description}
    \item[Full Citation:] Two-day cardiopulmonary exercise testing in long COVID post-exertional malaise diagnosis. \textit{Respiratory Medicine and Research}. 2024;85:101551.
    \item[DOI:] \href{https://doi.org/10.1016/j.resmer.2024.101551}{10.1016/j.resmer.2024.101551}
\end{description}

\begin{description}
    \item[Full Citation:] Recovery time from two-day CPET in ME/CFS. Cornell Center for Enervating NeuroImmune Disease. 2024.
    \item[URL:] \url{https://neuroimmune.cornell.edu/news/recovery-from-two-day-cpet-in-me-cfs/}
    \item[Key Findings:] Recovery $\sim$13 days in ME/CFS vs $\sim$2 days in sedentary controls.
\end{description}

% =============================================================================
\section{Treatment Evidence}
\label{sec:bib-treatment}
% =============================================================================

\subsection{Immunological Therapies: Rituximab and Cyclophosphamide}

\paragraph{Fluge et al.\ 2019 --- Rituximab Phase III Trial (NEGATIVE)}

\begin{description}
    \item[Full Citation:] Fluge Ø, Rekeland IG, Lien K, et al.\ B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. \textit{Annals of Internal Medicine}. 2019;170(9):585--593.
    \item[DOI:] \href{https://doi.org/10.7326/M18-1451}{10.7326/M18-1451}
    \item[PMID:] 30934066
    \item[Trial Registration:] ClinicalTrials.gov NCT02229942
    \item[Study Design:] Phase III randomized, double-blind, placebo-controlled, multicenter trial
    \item[Sample Size:] 151 patients (77 rituximab, 74 placebo)
\end{description}

\paragraph{Key Findings:}
\textbf{This trial was NEGATIVE.} Overall response rates were 35.1\% in the placebo group versus 26.0\% in the rituximab group (difference 9.2 percentage points [95\% CI: $-5.5$ to 23.3]; $p=0.22$). The treatment groups showed no differences in fatigue scores over 24 months (difference in average score 0.02 [CI: $-0.27$ to 0.31]; $p=0.80$) or any secondary endpoints (SF-36, physical function, activity levels). Serious adverse events occurred in 26.0\% of rituximab patients versus 18.9\% of placebo patients. Notably, the placebo response rate of 35\% demonstrates substantial natural fluctuation or expectation effects in ME/CFS.

\paragraph{Relevance:}
This landmark negative trial definitively refutes B-cell depletion as a therapeutic strategy for ME/CFS, contradicting earlier promising Phase II open-label studies from the same research group. The high placebo response rate (35\%) has critical implications for trial design: it demonstrates that even large apparent improvements in uncontrolled studies may not represent true drug effects. The study serves as a cautionary tale about extrapolating from small early-phase trials and emphasizes the necessity of rigorous placebo-controlled validation. \textbf{Rituximab should NOT be used for ME/CFS.}

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Quality:} High (Phase III RCT, double-blind, placebo-controlled, multicenter, published in \emph{Annals of Internal Medicine})
    \item \textbf{Sample:} n=151 (adequate for Phase III efficacy trial)
    \item \textbf{Replication:} This \emph{was} the replication---contradicted earlier positive Phase II results from same group
    \item \textbf{Funding:} Publicly funded (Norwegian Research Council, health trusts), no industry bias
    \item \textbf{Limitations:} Self-reported outcomes (though standard for ME/CFS); possible heterogeneity (small subset might respond but undetectable in overall analysis)
\end{itemize}

\paragraph{Rekeland et al.\ 2024 --- 6-Year Follow-up}

\begin{description}
    \item[Full Citation:] Rekeland IG, Sørland K, Neteland LL, et al.\ Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{PLoS One}. 2024;19(7):e0307484.
    \item[DOI:] \href{https://doi.org/10.1371/journal.pone.0307484}{10.1371/journal.pone.0307484}
    \item[PMID:] 39042627
    \item[PMCID:] PMC11265720
    \item[Study Type:] Long-term observational follow-up of RituxME (Phase III RCT) and CycloME (Phase II open-label) trials
\end{description}

\paragraph{Key Findings:}
At 6-year follow-up, rituximab showed no sustained benefit over placebo: 27.6\% of rituximab-treated patients achieved SF-36 Physical Function $\geq$70 compared to 20.4\% of placebo patients (not statistically significant). In contrast, the open-label cyclophosphamide group showed 44.1\% achieving SF-36 PF $\geq$70, with 17.6\% reaching normal function (PF $\geq$90). However, the authors explicitly caution: ``cyclophosphamide carries toxicity concerns and should not be used for ME/CFS patients outside clinical trials.'' The placebo group data provides valuable natural history information: approximately 20\% of patients improved substantially over 6 years without specific treatment, while 15\% worsened significantly.

\paragraph{Relevance:}
Confirms long-term lack of benefit for rituximab. The cyclophosphamide results are intriguing but \textbf{cannot be interpreted as evidence of efficacy} due to absence of placebo control, open-label design, small sample (n=34 at 6 years), and potential selection bias (94\% follow-up rate may favor responders). Given cyclophosphamide's severe toxicity (cancer risk, infertility, life-threatening infections), the uncertain benefit based solely on open-label data is insufficient to justify clinical use. The findings do, however, support the hypothesis of a possible immune-mediated subgroup and warrant investigation of safer immune-modulating agents with proper placebo-controlled trials.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Rituximab data:} High certainty of lack of benefit (follow-up of rigorous RCT)
    \item \textbf{Cyclophosphamide data:} Low certainty (no placebo control, open-label, small sample, selection bias)
    \item \textbf{Natural history data:} Moderate certainty (from placebo arm, but 24\% loss to follow-up)
    \item \textbf{Limitations:} Cyclophosphamide findings are hypothesis-generating only; different patient populations between trials complicate cross-comparison
\end{itemize}

\subsection{Low-Dose Naltrexone}

\paragraph{Polo et al.\ 2019 --- Retrospective Observational Study}

\begin{description}
    \item[Full Citation:] Polo O, Pesonen P, Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). \textit{Fatigue: Biomedicine, Health \& Behavior}. 2019;7(4):207--217.
    \item[DOI:] \href{https://doi.org/10.1080/21641846.2019.1692770}{10.1080/21641846.2019.1692770}
    \item[Published:] November 19, 2019
    \item[Study Design:] Retrospective chart review
    \item[Sample Size:] 218 ME/CFS patients
\end{description}

\paragraph{Key Findings:}
In this large retrospective analysis, 73.9\% (n=161/218) of ME/CFS patients reported subjective improvement with low-dose naltrexone (3.0--4.5 mg/day) over mean 1.7-year follow-up. Specific improvements included vigilance/alertness (51.4\%), physical performance (23.9\%), and cognitive function (21.1\%). No severe adverse events were reported; mild transient side effects (insomnia, nausea) occurred at treatment initiation but typically resolved. The authors explicitly acknowledge the study's limitations, concluding: ``placebo-controlled studies are needed to confirm these findings.''

\paragraph{Relevance:}
This is the largest observational study of LDN in ME/CFS, suggesting potential benefit with an excellent safety profile. However, \textbf{the absence of placebo control is a critical limitation.} Given that the rituximab trial demonstrated 35\% placebo response, the 74\% response rate to LDN in an open-label setting cannot be assumed to represent true drug effect. Additional concerns include retrospective design, subjective outcomes, selection bias (which patients were prescribed LDN?), and lack of validated outcome measures. That said, LDN's favorable safety profile, low cost (generic), and mechanistic plausibility (opioid receptor modulation, immune effects) make it a high-priority candidate for rigorous placebo-controlled RCT testing. Given the contrast with rituximab (both looked promising in early studies; rituximab failed RCT), this study should be viewed as hypothesis-generating rather than evidence of efficacy.

\paragraph{Certainty Assessment:}
\begin{itemize}
    \item \textbf{Safety:} High certainty (large sample, long follow-up, no serious adverse events)
    \item \textbf{Efficacy:} Low certainty (no placebo control, retrospective design, subjective outcomes)
    \item \textbf{Clinical Use:} May be reasonable for treatment-refractory patients with informed consent about uncertain evidence
    \item \textbf{Research Priority:} High (safe, cheap, worth rigorous RCT validation)
    \item \textbf{Limitations:} Retrospective, no placebo control (disqualifying for efficacy claims), undefined response criteria, no standardized dosing, single geographic location (Finland)
\end{itemize}

\subsection{Graded Exercise Therapy (Negative Evidence)}

\begin{description}
    \item[Full Citation:] Geraghty K, Hann M, Kurtev S. The Updated NICE Guidance Exposed the Serious Flaws in CBT and Graded Exercise Therapy Trials for ME/CFS. \textit{Healthcare}. 2022;10(5):898.
    \item[DOI:] \href{https://doi.org/10.3390/healthcare10050898}{10.3390/healthcare10050898}
    \item[PMCID:] PMC9141828
    \item[Key Findings:] Methodological flaws and biases in trials; patient surveys show harm from GET.
\end{description}

\begin{description}
    \item[Full Citation:] Vink M, Vink-Niese A. The PACE Trial's GET Manual for Therapists Exposes the Fixed Incremental Nature of Graded Exercise Therapy for ME/CFS. \textit{Life}. 2025;15(4):584.
    \item[DOI:] \href{https://doi.org/10.3390/life15040584}{10.3390/life15040584}
\end{description}

\begin{description}
    \item[Full Citation:] Vink M, Vink-Niese A. Graded exercise therapy does not restore the ability to work in ME/CFS -- Rethinking of a Cochrane review. \textit{Work}. 2020;66(2):283--308.
    \item[DOI:] \href{https://doi.org/10.3233/WOR-203174}{10.3233/WOR-203174}
    \item[PMID:] 32568149
\end{description}

\subsection{Pacing and Energy Management}

\begin{description}
    \item[Full Citation:] Goudsmit EM, Nijs J, Jason LA, Wallman KE. A scoping review of `Pacing' for management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): lessons learned for the long COVID pandemic. \textit{Journal of Translational Medicine}. 2023;21:738.
    \item[DOI:] \href{https://doi.org/10.1186/s12967-023-04586-6}{10.1186/s12967-023-04586-6}
    \item[PMCID:] PMC10576275
\end{description}

\begin{description}
    \item[Full Citation:] Jason LA, Brown M, Brown A, et al.\ Energy Conservation/Envelope Theory Interventions to Help Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. \textit{Fatigue: Biomedicine, Health \& Behavior}. 2013;1(1--2):65--78.
    \item[DOI:] \href{https://doi.org/10.1080/21641846.2012.733602}{10.1080/21641846.2012.733602}
    \item[PMCID:] PMC3596172
\end{description}

\subsection{Patient-Reported Treatment Outcomes}

\begin{description}
    \item[Full Citation:] Davis HE, McCorkell L, Vogel JM, et al.\ Patient-reported treatment outcomes in ME/CFS and long COVID. \textit{Proceedings of the National Academy of Sciences}. 2025;122(26):e2426874122.
    \item[DOI:] \href{https://doi.org/10.1073/pnas.2426874122}{10.1073/pnas.2426874122}
    \item[PMCID:] PMC12280984
    \item[Sample:] $>$3,900 patients
    \item[Key Findings:] Treatment responses highly correlated ($R^2$=0.68) between ME/CFS and Long COVID.
\end{description}

% =============================================================================
\section{Long COVID and ME/CFS Overlap}
\label{sec:bib-long-covid}
% =============================================================================

\begin{description}
    \item[Full Citation:] Thapaliya K, Marshall-Gradisnik S, Barber PA, Eaton-Fitch N, Staines D. Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies. \textit{Trends in Molecular Medicine}. 2024;30(5):443--458.
    \item[DOI:] \href{https://doi.org/10.1016/j.molmed.2024.02.003}{10.1016/j.molmed.2024.02.003}
    \item[PMID:] 38443223
\end{description}

\begin{description}
    \item[Full Citation:] Mapping the complexity of ME/CFS: Evidence for abnormal energy metabolism, altered immune profile, and vascular dysfunction. \textit{Cell Reports Medicine}. 2025;6(12):101587.
    \item[DOI:] \href{https://doi.org/10.1016/j.xcrm.2025.101587}{10.1016/j.xcrm.2025.101587}
\end{description}

% =============================================================================
\section{Historical Background and Epidemics}
\label{sec:bib-history}
% =============================================================================

\begin{description}
    \item[Full Citation:] Underhill RA. Myalgic encephalomyelitis, chronic fatigue syndrome: An infectious disease. \textit{Medical Hypotheses}. 2015;85(6):765--773.
    \item[DOI:] \href{https://doi.org/10.1016/j.mehy.2015.10.011}{10.1016/j.mehy.2015.10.011}
    \item[Topics:] Historical outbreaks from 1934 onwards.
\end{description}

\begin{description}
    \item[Full Citation:] Underhill RA, O'Gorman R. The viral origin of myalgic encephalomyelitis/chronic fatigue syndrome. \textit{Journal of the Royal Society of Medicine}. 2023;116(8):269--282.
    \item[DOI:] \href{https://doi.org/10.1177/01410768231176937}{10.1177/01410768231176937}
    \item[PMCID:] PMC10434940
\end{description}

\begin{description}
    \item[Full Citation:] Brurberg KG, Fønhus MS, Larun L, Flottorp S, Malterud K. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Organic Disease or Psychosomatic Illness? A Re-Examination of the Royal Free Epidemic of 1955. \textit{Medicina}. 2021;57(1):12.
    \item[DOI:] \href{https://doi.org/10.3390/medicina57010012}{10.3390/medicina57010012}
    \item[PMID:] 33375343
    \item[Key Findings:] First-hand accounts confirm organic infectious disease, not hysteria.
\end{description}

\begin{description}
    \item[Full Citation:] Jason LA, Lapp CW, Engel S, et al.\ Myalgic Encephalomyelitis (ME) outbreaks can be modelled as an infectious disease: a mathematical reconsideration of the Royal Free Epidemic of 1955. \textit{Fatigue: Biomedicine, Health \& Behavior}. 2020;8(2):99--109.
    \item[DOI:] \href{https://doi.org/10.1080/21641846.2020.1793058}{10.1080/21641846.2020.1793058}
\end{description}

% =============================================================================
\section{Research Roadmaps and Policy Documents}
\label{sec:bib-policy}
% =============================================================================

\begin{description}
    \item[Full Citation:] National Institute of Neurological Disorders and Stroke. Report of the ME/CFS Research Roadmap Working Group of Council. Bethesda, MD: NINDS; May 15, 2024.
    \item[URL:] \url{https://www.ninds.nih.gov/sites/default/files/2024-05/Report\%20of\%20the\%20MECFS\%20Research\%20Roadmap\%20Working\%20Group\%20of\%20Council_508C.pdf}
    \item[Significance:] Official NIH research priorities and funding recommendations.
\end{description}

\begin{description}
    \item[Full Citation:] Reframing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Biological Basis of Disease and Recommendations for Supporting Patients. 2025.
    \item[PMCID:] PMC12346739
\end{description}

% =============================================================================
\section{Comprehensive Reviews}
\label{sec:bib-comprehensive-reviews}
% =============================================================================

\begin{description}
    \item[Full Citation:] Cortes Rivera M, Mastronardi C, Silva-Aldana CT, Arcos-Burgos M, Lidbury BA. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review. \textit{Diagnostics}. 2019;9(3):91.
    \item[DOI:] \href{https://doi.org/10.3390/diagnostics9030091}{10.3390/diagnostics9030091}
    \item[PMCID:] PMC6787585
\end{description}

% =============================================================================
% =============================================================================
\section{Mast Cell Activation and Antihistamine Therapies}
\label{sec:bib-mast-cell-antihistamines}
% =============================================================================

\subsection{Hardcastle et al.\ 2016 --- Mast Cell Phenotype Abnormalities in ME/CFS}

\begin{description}
    \item[Full Citation:] Hardcastle SL, Brenu EW, Johnston S, et al.\ Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients. \textit{BMC Immunology}. 2016;17(1):30.
    \item[DOI:] \href{https://doi.org/10.1186/s12865-016-0167-z}{10.1186/s12865-016-0167-z}
    \item[PMID:] 27362406
    \item[PMCID:] PMC4928291
    \item[Published:] June 29, 2016
    \item[Study Design:] Cross-sectional immunophenotyping study
    \item[Sample Size:] 18 ME/CFS patients (12 moderate, 6 severe), 13 matched healthy controls
    \item[Key Findings:]
    \begin{itemize}
        \item Significant increase in naïve mast cells (CD117$^+$CD34$^+$Fc$\varepsilon$RI$^-$chymase$^-$) in moderate and severe ME/CFS ($p<0.05$)
        \item Elevated CD40 ligand and MHC-II receptors on differentiated mast cells in severe ME/CFS
        \item Demonstrates measurable mast cell abnormalities at cellular level
        \item Supports hypothesis that mast cells may be involved in ME/CFS pathophysiology
    \end{itemize}
    \item[Certainty:] High (well-designed study, statistically significant findings)
    \item[Clinical Relevance:] Provides biological basis for mast cell involvement in ME/CFS; supports rationale for mast cell-targeted therapies
\end{description}

\subsection{Wirth \& Scheibenbogen 2023 --- Mast Cell Activation and Vascular Pathomechanisms}

\begin{description}
    \item[Full Citation:] Wirth K, Scheibenbogen C. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Comorbidities: Linked by Vascular Pathomechanisms and Vasoactive Mediators? \textit{Healthcare}. 2023;11(7):978.
    \item[DOI:] \href{https://doi.org/10.3390/healthcare11070978}{10.3390/healthcare11070978}
    \item[PMID:] 37046903
    \item[PMCID:] PMC10224216
    \item[Published:] March 27, 2023
    \item[Study Type:] Review and hypothesis paper
    \item[Key Mechanisms:]
    \begin{itemize}
        \item Mast cell activation shares pathogenic mechanisms with ME/CFS through excessive histamine, heparin, prostaglandins, leukotrienes, and protease release
        \item Spillover of vasoactive mediators into systemic circulation worsens orthostatic intolerance via histamine's vascular effects
        \item $\beta_2$-adrenergic receptor dysfunction amplifies symptoms
        \item ME/CFS patients with MCAS and orthostatic intolerance reported symptom alleviation significantly more often following mast cell-targeted treatment ($p<0.0001$)
    \end{itemize}
    \item[Certainty:] Medium (mechanistic hypothesis with clinical correlation)
    \item[Clinical Relevance:] Links mast cell activation to orthostatic intolerance; suggests mast cell-targeted therapies may benefit subset of ME/CFS patients with vascular/autonomic symptoms
\end{description}

\subsection{Novak et al.\ 2022 --- Mast Cell Disorders, Cerebral Hypoperfusion, and Small Fiber Neuropathy}

\begin{description}
    \item[Full Citation:] Novak P, Giannetti MP, Weller E, Hamilton MJ, Castells M. Mast cell disorders are associated with decreased cerebral blood flow and small fiber neuropathy. \textit{Ann Allergy Asthma Immunol}. 2022;128(3):299--306.e1.
    \item[DOI:] \href{https://doi.org/10.1016/j.anai.2021.10.006}{10.1016/j.anai.2021.10.006}
    \item[PMID:] 34648976
    \item[Published:] March 2022
    \item[Study Design:] Case-control study with objective neurological measurements
    \item[Sample Size:] 15 hereditary alpha tryptasemia (H$\alpha$T), 16 mast cell activation syndrome (MCAS), 14 matched controls
    \item[Key Findings:]
    \begin{itemize}
        \item \textbf{Small fiber neuropathy highly prevalent}: 80\% of H$\alpha$T and 81\% of MCAS patients (vs controls, $p<0.001$)
        \item \textbf{Cerebral hypoperfusion during orthostatic stress}: CBFv reduced $-24.2\pm14.3\%$ in H$\alpha$T, $-20.8\pm5.5\%$ in MCAS (vs controls $+2.3\pm8.1\%$, $p<0.001$)
        \item \textbf{Universal dysautonomia}: All patients showed abnormalities when sympathetic, parasympathetic, and sudomotor tests combined
        \item Similar outcomes despite different tryptase levels (H$\alpha$T: $14.3\pm2.5$ ng/mL vs MCAS: $3.8\pm1.8$ ng/mL) --- suggests common final pathway
    \end{itemize}
    \item[Certainty:] High (objective measurements, rigorous protocols, appropriate controls)
    \item[Clinical Relevance:] \textbf{Critical for ME/CFS} --- provides objective biomarkers for mast cell-mediated neurological dysfunction. The 80\% SFN prevalence, cerebral hypoperfusion, and dysautonomia mirror ME/CFS findings, suggesting MCAS screening in ME/CFS patients with severe orthostatic intolerance. Testable via autonomic testing battery, transcranial Doppler, and skin biopsy.
\end{description}

\subsection{Magadmi et al.\ 2019 --- CADM1-Mediated Mast Cell-Nerve Adhesion Amplifies Inflammation}

\begin{description}
    \item[Full Citation:] Magadmi R, Meszaros J, Damanhouri ZA, Seward EP. CADM1-dependent adhesion between mast cells and sensory neurons enhances mast cell inflammatory responses. \textit{Front Cell Neurosci}. 2019;13:262.
    \item[DOI:] \href{https://doi.org/10.3389/fncel.2019.00262}{10.3389/fncel.2019.00262}
    \item[Published:] 2019
    \item[Study Design:] In vitro mechanistic study (mouse cells)
    \item[Key Findings:]
    \begin{itemize}
        \item CADM1 protein mediates physical adhesion between mast cells and sensory neurons
        \item Neuronal contact amplifies mast cell degranulation (~2-fold) and IL-6 secretion (~3-fold)
        \item Blocking CADM1 abolished enhancement --- demonstrates adhesion requirement
        \item Effect is neuron-specific (HEK 293 cells expressing CADM1 did not replicate) --- suggests additional neuronal signals
        \item TNF$\alpha$ unchanged --- indicates selective pathway modulation
    \end{itemize}
    \item[Certainty:] Medium (well-controlled in vitro study, but mouse cells; awaits human and in vivo validation)
    \item[Clinical Relevance:] Provides mechanistic support for ``signal amplifier hypothesis'' of mast cell-nerve interactions in ME/CFS. Could explain pain amplification disproportionate to tissue damage and the connection between mast cell activation and small fiber neuropathy documented in Novak et al.\ 2022.
\end{description}

\subsection{Nakamura et al.\ 2014 --- Circadian Clock Regulates Mast Cell Function}

\begin{description}
    \item[Full Citation:] Nakamura Y, Nakano N, Ishimaru K, et al. Circadian regulation of allergic reactions by the mast cell clock in mice. \textit{J Allergy Clin Immunol}. 2014;133(2):568--575.
    \item[DOI:] \href{https://doi.org/10.1016/j.jaci.2013.07.040}{10.1016/j.jaci.2013.07.040}
    \item[PMID:] 24060274
    \item[Published:] February 2014
    \item[Study Design:] Genetic mouse model with circadian clock manipulation
    \item[Key Findings:]
    \begin{itemize}
        \item Mast cells possess intrinsic circadian clocks that drive time-of-day variation in degranulation
        \item \textit{Clock} gene mutation abolished temporal variation in IgE-mediated responses (both in vivo and in vitro)
        \item Fc$\varepsilon$RI receptor expression and signaling show circadian rhythms in wild-type cells, lost in \textit{Clock}-mutant
        \item Adrenalectomy disrupts mast cell clock rhythms --- demonstrates adrenal hormones entrain mast cell clocks
    \end{itemize}
    \item[Certainty:] High for mechanism (elegant genetics, replicated); Low-Medium for ME/CFS relevance (extrapolation from mouse allergy model)
    \item[Clinical Relevance:] Provides basis for ``temporal priming hypothesis'' --- HPA axis dysfunction in ME/CFS could disrupt mast cell circadian regulation, leading to inappropriate activation timing. May explain symptom timing patterns, sleep-symptom interactions, and potential for chronotherapy (timing mast cell treatments to peak reactivity periods).
\end{description}

\subsection{Steinberg et al.\ 1996 --- Terfenadine Trial (Negative)}

\begin{description}
    \item[Full Citation:] Steinberg P, McNutt BE, Marshall P, et al.\ A double-blind placebo-controlled study of the efficacy of oral terfenadine in the chronic fatigue syndrome. \textit{J Allergy Clin Immunol}. 1996;97(1 Pt 1):119--126.
    \item[DOI:] \href{https://doi.org/10.1016/S0091-6749(96)80212-6}{10.1016/S0091-6749(96)80212-6}
    \item[PMID:] 8568124
    \item[Published:] January 1996
    \item[Study Design:] Double-blind, placebo-controlled RCT
    \item[Sample Size:] 30 CFS patients enrolled, 28 completed
    \item[Intervention:] Terfenadine 60 mg twice daily for 8 weeks (H1 antihistamine only)
    \item[Results:]
    \begin{itemize}
        \item \textbf{NO therapeutic benefit detected}
        \item No improvement in symptom amelioration
        \item No improvement in physical or social functioning
        \item No improvement in health perceptions or mental health
        \item Additional finding: 73\% had atopy, 53\% had positive immediate skin test results
    \end{itemize}
    \item[Conclusion:] ``Terfenadine is unlikely to be of clinical benefit in treating CFS symptoms''
    \item[Certainty:] High (well-designed RCT with negative results)
    \item[Clinical Implications:] H1 antihistamine alone insufficient; suggests combination therapy (H1+H2 or H1+mast cell stabilizer) may be necessary
\end{description}

\subsection{Davis et al.\ 2023 --- Long COVID Case with H1/H2 Combination Success}

\begin{description}
    \item[Full Citation:] Davis HE, McCorkell L, Vogel JM, Topol EJ. Case Study of ME/CFS Care Applied to Long COVID: Hypothesis Regarding Exercise Intolerance, Orthostatic Intolerance, Mast Cell Activation, Sleep Dysfunction, Neuropathy, and Viral Persistence. \textit{Healthcare}. 2023;11(6):896.
    \item[DOI:] \href{https://doi.org/10.3390/healthcare11060896}{10.3390/healthcare11060896}
    \item[PMID:] 36981567
    \item[PMCID:] PMC10048325
    \item[Published:] March 21, 2023
    \item[Study Type:] Single case report (n=1)
    \item[Patient:] Long COVID patient meeting ME/CFS criteria
    \item[Interventions and Outcomes:]
    \begin{itemize}
        \item \textbf{H1 blockers} (loratadine 10 mg OR fexofenadine 180 mg): ``helpful with energy and cognitive dysfunction''
        \item \textbf{H2 blocker} (famotidine 40 mg BID): ``helpful with energy and cognitive dysfunction''
        \item \textbf{Discontinuation test}: Stopping fexofenadine and famotidine $\rightarrow$ ``increased fatigue and increased cognitive dysfunction, both of which improved rapidly upon resumption''
        \item \textbf{Cromolyn} (400 mg QID): Peak heart rate during walking fell from 130--140 bpm to 100--105 bpm
        \item \textbf{Quercetin} (1000 mg BID): ``Improvement in fatigue and allergic symptoms''
    \end{itemize}
    \item[Certainty:] Low (n=1 case report, but dramatic response with discontinuation-rechallenge confirmation)
    \item[Clinical Relevance:] Demonstrates potential for H1+H2 combination therapy; suggests mast cell-targeted approach may benefit post-viral fatigue syndromes
\end{description}

\subsection{Theoharides et al.\ 2012 --- Quercetin Superior to Cromolyn}

\begin{description}
    \item[Full Citation:] Theoharides TC, Asadi S, Panagiotidou S. Quercetin in combination with IL-6 inhibits histamine and TNF release from mast cells through interaction with the IL-6 receptor. \textit{PLOS ONE}. 2012;7(3):e33805.
    \item[DOI:] \href{https://doi.org/10.1371/journal.pone.0033805}{10.1371/journal.pone.0033805}
    \item[PMID:] 22470478
    \item[PMCID:] PMC3314669
    \item[Published:] March 29, 2012
    \item[Study Design:] In vitro comparison + clinical pilot trials
    \item[Concentration:] Quercetin 100 $\mu$M (approximated by 2 g/day oral dosing)
    \item[Key Findings:]
    \begin{itemize}
        \item \textbf{IgE/Anti-IgE stimulation}: Quercetin inhibited histamine (82\% vs 67\%), PGD$_2$ (77\% vs 75\%), leukotrienes (99\% vs 88\%) comparably to cromolyn
        \item \textbf{Substance P stimulation}: Quercetin dramatically outperformed cromolyn --- IL-8 reduced from 437.2 to 115.4 pg/mL (quercetin) vs 362.9 pg/mL (cromolyn)
        \item \textbf{Mechanism}: Quercetin worked prophylactically (30 min pre-stimulus); cromolyn required simultaneous addition
        \item \textbf{Clinical trial --- Contact dermatitis}: Quercetin 2 g/day for 3 days reduced nickel patch reactions $>$50\% in 8 of 10 patients; pruritus eliminated completely
        \item \textbf{Clinical trial --- Photosensitivity}: Quercetin 1 g increased minimal erythema dose in all patients ($p$=0.002)
    \end{itemize}
    \item[Certainty:] Medium-High (strong in vitro data, pilot clinical success)
    \item[Clinical Relevance:] Quercetin may be superior to prescription cromolyn for mast cell stabilization; available over-the-counter; well-tolerated
\end{description}

\subsection{Clemons et al.\ 2011 --- Amitriptyline Mast Cell Inhibition}

\begin{description}
    \item[Full Citation:] Clemons A, Vasiadi M, Kempuraj D, et al.\ Amitriptyline and prochlorperazine inhibit proinflammatory mediator release from human mast cells: possible relevance to chronic fatigue syndrome. \textit{J Clin Psychopharmacol}. 2011;31(3):385--387.
    \item[DOI:] \href{https://doi.org/10.1097/JCP.0b013e3182196e50}{10.1097/JCP.0b013e3182196e50}
    \item[PMID:] 21532369
    \item[PMCID:] PMC3498825
    \item[Published:] June 2011
    \item[Study Design:] In vitro study on human mast cells
    \item[Key Findings:]
    \begin{itemize}
        \item Amitriptyline (AMI) and prochlorperazine (PRO) at 25 $\mu$M significantly reduced IL-8, VEGF, and IL-6 release from stimulated human mast cells
        \item Bupropion, citalopram, and atomoxetine did NOT inhibit mast cells
        \item Mechanism involves modulation of intracellular calcium (FURA2 AM calcium indicator assays)
        \item AMI inhibits histamine release while permitting serotonin release
    \end{itemize}
    \item[Conclusion:] ``The ability of amitriptyline, but not other antidepressants, to inhibit human mast cell release of pro-inflammatory cytokines may be relevant to their apparent benefit in CFS''
    \item[Certainty:] Medium (mechanistic in vitro study, explains clinical observations)
    \item[Clinical Relevance:] Amitriptyline's benefit in ME/CFS may involve mast cell inhibition beyond pain/sleep effects; specific pharmacological mechanism
\end{description}

\subsection{Rupatadine --- Dual H1/PAF Antagonist with Mast Cell Stabilization}

\begin{description}
    \item[Full Citations:]
    \begin{itemize}
        \item Piñero-González J, et al.\ Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli. \textit{J Investig Allergol Clin Immunol}. 2017;27(3):161--168. PMID: 19672095; PMCID: PMC7065400.
        \item Mullol J, Bousquet J, Bachert C, et al.\ Rupatadine in allergic rhinitis and chronic urticaria. \textit{Allergy}. 2008;63(Suppl 87):5--28. PMID: 18339040.
    \end{itemize}
    \item[Mechanism:] Triple action --- (1) H1 receptor antagonist, (2) PAF (platelet-activating factor) antagonist, (3) Direct mast cell stabilizer
    \item[Mast Cell Effects:]
    \begin{itemize}
        \item Rupatadine (10--50 $\mu$M) inhibited IL-8 (80\%), VEGF (73\%), histamine (88\%) release from LAD2 mast cell line
        \item Also inhibited IL-6, IL-8, IL-10, IL-13, and TNF release from human cord blood-derived cultured mast cells
        \item More effective than levocetirizine and desloratadine at PAF-induced mast cell inhibition
    \end{itemize}
    \item[PAF Antagonism Potency:]
    \begin{itemize}
        \item Rupatadine IC$_{50}$ = 4.6 $\mu$M (most potent)
        \item Loratadine IC$_{50}$ = 142 $\mu$M ($\sim$31$\times$ less potent)
        \item Cetirizine IC$_{50}$ $>$200 $\mu$M ($>$43$\times$ less potent)
        \item Fexofenadine IC$_{50}$ $>$200 $\mu$M ($>$43$\times$ less potent)
    \end{itemize}
    \item[Efficacy Ranking:] Network meta-analysis for allergic rhinitis (SUCRA scores):
    \begin{itemize}
        \item Rupatadine 20 mg: 99.7\% (highest rank)
        \item Rupatadine 10 mg: 76.3\%
        \item Fexofenadine, cetirizine: moderate
        \item Loratadine 10 mg: lowest (inferior to all others)
    \end{itemize}
    \item[Certainty:] High (multiple RCTs, network meta-analysis, in vitro mechanistic data)
    \item[Clinical Relevance:] Superior to standard H1 antihistamines; unique PAF antagonism may benefit ME/CFS patients with mast cell activation and vascular/orthostatic symptoms
    \item[Note:] PAF is a key inflammatory mediator in ME/CFS contributing to vascular leakage, brain fog, and orthostatic issues
\end{description}

\subsection{Moldofsky et al.\ 2015 --- Ketotifen in Fibromyalgia (Negative)}

\begin{description}
    \item[Full Citation:] Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S. A randomized, double-blind, placebo-controlled Phase 1 trial of ketotifen in fibromyalgia. \textit{J Rheumatol}. 2015;42(12):2505--2513.
    \item[DOI:] \href{https://doi.org/10.3899/jrheum.150460}{10.3899/jrheum.150460}
    \item[PMID:] 26472411
    \item[PMCID:] PMC4417653
    \item[Published:] December 2015
    \item[Study Design:] Phase 1 RCT, double-blind, placebo-controlled
    \item[Sample Size:] 51 fibromyalgia patients (24 ketotifen, 27 placebo)
    \item[Intervention:] Ketotifen 2 mg BID for 8 weeks (after 1-week titration)
    \item[Results:] \textbf{NO significant differences} in primary outcomes:
    \begin{itemize}
        \item Pain intensity: ketotifen $-1.3$ vs placebo $-1.5$ ($p$=0.7)
        \item FIQR scores: $-12.1$ vs $-12.2$ ($p$=0.9)
        \item Side effect: Transient sedation 28.6\% vs 4\%
    \end{itemize}
    \item[Certainty:] High (well-designed RCT showing no benefit)
    \item[Clinical Relevance:] Mast cell stabilization alone may not address core pathophysiology in central pain syndromes like fibromyalgia; relevance to ME/CFS unclear
    \item[Note:] Despite this negative finding, retrospective ME/CFS study (not included here) showed 77\% of continuers had significant PEM reduction with ketotifen
\end{description}

% =============================================================================
\section{Blood Volume and Cardiovascular Dysfunction}
\label{sec:bib-blood-volume}
% =============================================================================

\subsection{Hypovolemia and RAAS Dysfunction}

Chronic hypovolemia (reduced blood volume) is a well-documented feature of ME/CFS, with direct consequences for oxygen delivery, exercise capacity, and orthostatic symptoms. Paradoxically, the renin-angiotensin-aldosterone system (RAAS) and antidiuretic hormone (ADH) --- which normally activate in response to low blood volume --- show suppression in ME/CFS patients.

\paragraph{Miwa \& Fujita 2017~\cite{Miwa2017}:}
This study identified paradoxical down-regulation of volume-regulatory hormones in ME/CFS. Despite documented hypovolemia and reduced cardiac output, plasma aldosterone was 33\% lower (104±37 vs 157±67 pg/ml, $p$=0.004) and ADH was 33\% lower (2.2±1.0 vs 3.3±1.5 pg/ml, $p$=0.02) compared to healthy controls (n=14 patients, n=13 controls). Treatment trial: desmopressin (ADH analog) improved orthostatic symptoms in 50\% of patients. \textbf{Certainty:} Medium (peer-reviewed, significant findings, but small sample awaiting replication). \textbf{Implication:} Hypovolemia results from central dysregulation of volume-regulatory systems, not excessive fluid loss.

\paragraph{Raj et al.\ 2005~\cite{Raj2005}:}
Landmark study demonstrating the ``renin-aldosterone paradox'' in postural tachycardia syndrome (POTS), a condition overlapping with ME/CFS. Blood volume was markedly reduced (3583±579 vs 4319±578 mL, $p$<0.0001), with plasma volume 21\% lower (2172±429 vs 2763±437 mL, $p$<0.0001). Despite this, plasma renin activity was unchanged and aldosterone was frankly low (7.0±5.3 vs 12.3±6.4 ng/dL, $p$=0.01). Strong positive correlation between blood volume and aldosterone (r=0.56, $p$=0.001). n=33 POTS patients, n=13 controls. \textbf{Certainty:} High (large sample, replicated, published in \textit{Circulation}).

\paragraph{Mustafa et al.\ 2011~\cite{Mustafa2011}:}
Identified abnormalities in angiotensin II regulation in POTS. Plasma Ang II was significantly elevated (43±3 vs 28±3 pg/mL, $p$=0.006), while estimated ACE2 activity was reduced (0.25±0.02 vs 0.33±0.03, $p$=0.038). Elevated Ang II may contribute to peripheral vasoconstriction and reduced NO bioavailability. \textbf{Certainty:} Medium-High (peer-reviewed, mechanistic insight into RAAS dysfunction).

\paragraph{Stewart et al.\ 2006~\cite{Stewart2006}:}
Increased plasma angiotensin II in low-flow POTS patients related to reduced blood flow and blood volume. Suggests Ang II elevation is compensatory attempt to maintain blood pressure despite hypovolemia, but may contribute to local blood flow dysregulation. \textbf{Certainty:} Medium (mechanistic study linking Ang II to blood volume deficit).

\paragraph{Farquhar et al.\ 2002~\cite{Farquhar2002}:}
Early study demonstrating relationship between blood volume and exercise capacity in CFS. Patients had significantly lower peak VO$_2$ consumption with trend toward lower blood volume. Strong correlation between blood volume and peak oxygen consumption, suggesting hypovolemia as physiological contributor to exercise intolerance. \textbf{Certainty:} Medium (established blood volume-exercise link).

\paragraph{van Campen et al.\ 2018~\cite{vanCampen2018}:}
Dual-isotope blood volume measurement in ME/CFS adults. Mean absolute blood volume was 59(8) ml/kg, representing -11(7) ml/kg deficit below reference values. Blood volume reduction correlated with presence of orthostatic intolerance symptoms (n=20). \textbf{Certainty:} High (precise measurement technique, clear clinical correlation).

\subsection{Cardiac Dysfunction and Natriuretic Peptides}

\paragraph{Newton et al.\ 2016~\cite{Newton2016}:}
CFS patients had significantly reduced cardiac volumes (both end-systolic and end-diastolic) with reduced end-diastolic wall masses. Strong positive correlations between total blood volume, red cell volume, plasma volume and cardiac end-diastolic wall mass. Critically, no relationship between disease length and cardiac/plasma volumes, ruling out deconditioning as sole cause. \textbf{Certainty:} High (cardiac MRI, objective measures, n=42 CFS patients). \textbf{Implication:} Reduced cardiac volumes are primary feature, not secondary to inactivity.

\paragraph{Tomas et al.\ 2017~\cite{Tomas2017}:}
Brain natriuretic peptide (BNP) levels significantly elevated in CFS cohort ($p$=0.013). Patients with high BNP (>400 pg/mL) had significantly lower cardiac volumes in both end-systolic and end-diastolic measurements ($p$=0.05). BNP elevation associated with cardiac dysfunction, not just volume overload. \textbf{Certainty:} Medium-High (established biomarker, cardiac imaging correlation).

\subsection{Endothelial Dysfunction and Vascular Pathology}

\paragraph{Scherbakov et al.\ 2020~\cite{Scherbakov2020}:}
Peripheral endothelial dysfunction found in 51\% of ME/CFS patients vs 20\% of healthy controls ($p$<0.05). Endothelial dysfunction assessed via flow-mediated dilation. Associated with disease severity and severity of immune symptoms (n=35 patients). \textbf{Certainty:} High (objective vascular measurement, peer-reviewed, ESC Heart Failure). \textbf{Implication:} Vascular pathology contributes to reduced blood flow and tissue perfusion.

\paragraph{Appel et al.\ 2024~\cite{Appel2025}:}
Comprehensive review of endothelial dysfunction in ME/CFS. Elevated adhesion molecules (ICAM-1, VCAM-1), impaired flow-mediated dilation, chronic inflammatory state contributing to vascular pathology. Links endothelial dysfunction to exercise intolerance and post-exertional symptoms. \textbf{Certainty:} High (systematic review, multiple lines of evidence).

\paragraph{Miller et al.\ 2020~\cite{Miller2020arterial}:}
Arterial elasticity significantly increased in Ehlers-Danlos syndrome patients. Central pulse wave velocity significantly lower in EDS (4.73 m/s vs controls), indicating increased arterial elasticity that impairs baroreceptor-mediated blood pressure control. Explains orthostatic intolerance mechanism in EDS and related hypermobility conditions. n=46 EDS patients across multiple subtypes (primarily hEDS). \textbf{Certainty:} High (objective arterial measurements, published in \textit{Genes}, significant finding). \textbf{Relevance to ME/CFS:} High comorbidity between ME/CFS and hEDS/hypermobility spectrum disorders. Increased arterial compliance reduces effectiveness of baroreceptor responses, contributing to orthostatic intolerance and POTS. Provides vascular mechanism linking connective tissue disorders to autonomic symptoms common in ME/CFS population.

\subsection{Erythropoiesis and Red Blood Cell Function}

\paragraph{Streeten DHP, Bell DS. 1998~\cite{Streeten1998blood}:}
Landmark early study measuring circulating blood volume in CFS patients using radiolabeled RBC and plasma volume techniques. Found: red blood cell mass reduced in 93.8\% of female and 50\% of male ME/CFS patients; plasma volume subnormal in 52.6\%. Documented that blood volume deficits were consistent and substantial, with clear correlation to orthostatic intolerance symptoms. Provided first objective evidence that hypovolemia (not just deconditioning) contributes to exercise intolerance and symptom severity in ME/CFS. \textbf{Certainty:} High (gold-standard blood volume measurement technique, clear patient selection, objective methodology). \textbf{Clinical Implication:} Hypovolemia is a primary physiological feature of ME/CFS, not secondary consequence.

\paragraph{Saha et al.\ 2019~\cite{Saha2019}:}
Red blood cell deformability significantly reduced in CFS patients using microfluidic measurements. Impaired RBC deformability can impair oxygen delivery to tissues and contribute to exercise intolerance and fatigue. n=20 CFS, n=20 controls. \textbf{Certainty:} Medium-High (novel methodology, replicated findings, published in clinical journal). \textbf{Implication:} Even with adequate RBC count, oxygen delivery may be compromised.

\paragraph{Winkler et al.\ 2004~\cite{Winkler2004}:}
Evaluation of serum erythropoietin levels and autonomic function in CFS. Examined potential relationships with anemia and fatigue severity. \textbf{Certainty:} Medium (exploratory study).

\paragraph{Świątczak et al.\ 2022~\cite{Swiatczak2022}:}
CFS patients show deteriorated iron metabolism: low serum iron, elevated ferritin, reduced transferrin saturation --- pattern consistent with inflammatory anemia. Not true iron deficiency but iron sequestration due to inflammation. \textbf{Certainty:} Medium-High (clear pattern, n=multiple cohorts). \textbf{Link to cytokines:} IL-6 and hepcidin drive iron restriction.

\paragraph{Morceau et al.\ 2009~\cite{Morceau2010}:}
Mechanistic review: pro-inflammatory cytokines (IL-1, IL-6, TNF-$\alpha$, IFN-$\gamma$) suppress erythropoiesis via multiple pathways including hepcidin induction, direct EPO suppression, and shortened RBC lifespan. \textbf{Relevance to ME/CFS:} Elevated cytokines documented in ME/CFS may contribute to functional anemia.

\paragraph{McCranor et al.\ 2014~\cite{McCranor2014}:}
IL-6 directly impairs erythroid differentiation in vitro, providing mechanistic link between cytokine elevation and anemia of chronic disease. \textbf{Certainty:} High (mechanistic study, controlled conditions).

\paragraph{Fraenkel 2017~\cite{Fraenkel2017}:}
Comprehensive review of anemia of inflammation: cytokine-mediated suppression of erythropoiesis, hepcidin-induced iron restriction, shortened RBC survival. \textbf{Application to ME/CFS:} Framework for understanding functional anemia despite normal hemoglobin in some patients.

\subsection{Integrated Mechanisms: The Hypovolemia Cascade}

The blood volume deficit in ME/CFS results from convergent mechanisms:

\begin{enumerate}
    \item \textbf{RAAS/ADH suppression:} Paradoxical down-regulation prevents compensatory volume retention (Miwa 2017, Raj 2005)
    \item \textbf{Plasma volume reduction:} Primary deficit in fluid compartment (Raj 2005: 21\% reduction; van Campen 2018: -11 ml/kg)
    \item \textbf{Cardiac consequences:} Reduced preload → reduced cardiac output → exercise intolerance (Newton 2016)
    \item \textbf{Endothelial dysfunction:} Impaired vascular regulation → tissue hypoperfusion (Scherbakov 2020)
    \item \textbf{RBC dysfunction:} Reduced deformability + inflammatory anemia → impaired oxygen delivery (Saha 2019, Świątczak 2022)
    \item \textbf{Cytokine-mediated effects:} IL-6 and other cytokines suppress erythropoiesis and sequester iron (Morceau 2009, McCranor 2014)
\end{enumerate}

This multi-hit model explains why simple volume expansion (saline infusion) provides only temporary benefit: underlying regulatory systems remain dysfunctional.

\paragraph{Clinical Implications:}
\begin{itemize}
    \item \textbf{Diagnostics:} Dual-isotope blood volume measurement may identify hypovolemic subgroup
    \item \textbf{Treatment targets:} Desmopressin for ADH-deficient patients (Miwa 2017); fludrocortisone for aldosterone supplementation; management of endothelial dysfunction; optimization of iron availability despite inflammation
    \item \textbf{Subtype identification:} Not all ME/CFS patients show same degree of hypovolemia; responders to volume-expanding interventions may represent distinct subgroup
\end{itemize}

\paragraph{Research Gaps:}
\begin{itemize}
    \item Mechanism of RAAS/ADH suppression (central dysregulation? autoimmune?)
    \item Predictors of desmopressin response
    \item Longitudinal blood volume changes over disease course
    \item Relationship between blood volume deficit and PEM severity
    \item Role of capillary permeability in plasma volume loss
\end{itemize}

\section{Additional Key Resources}
\label{sec:bib-resources}
% =============================================================================

\subsection{Patient Advocacy and Information}

\begin{description}
    \item[MEpedia:] \url{https://me-pedia.org/} --- Comprehensive patient-edited wiki on ME/CFS.
    \item[ME Association (UK):] \url{https://meassociation.org.uk/} --- Patient support and research summaries.
    \item[Bateman Horne Center:] \url{https://batemanhornecenter.org/} --- Clinical and educational resources.
    \item[Open Medicine Foundation:] \url{https://www.openmedicinefoundation.ngo/} --- Research funding and updates.
    \item[Solve ME/CFS Initiative:] \url{https://solvecfs.org/} --- US-based research and advocacy.
\end{description}

\subsection{Research Centers}

\begin{description}
    \item[Cornell Center for Enervating NeuroImmune Disease:] \url{https://neuroimmune.cornell.edu/}
    \item[Griffith University National Centre for Neuroimmunology and Emerging Diseases:] Queensland, Australia
    \item[Charit\'e Fatigue Center:] Berlin, Germany
    \item[Stanford ME/CFS Initiative:] Stanford University, California
\end{description}

\vspace{1cm}
\begin{center}
\rule{0.5\textwidth}{0.4pt}
\end{center}
\vspace{0.5cm}

\noindent\textit{Note: This bibliography was compiled in January 2025. The field of ME/CFS research is rapidly evolving, particularly with insights from Long COVID research. Readers are encouraged to search PubMed and preprint servers for the most current literature.}